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ABSTRACT OF THE DISSERTATION
Regulation of metabolic stress-induced snoRNAs
by
Benjamin Steel Scruggs
Doctor of Philosophy in Biology and Biomedical Sciences
(Molecular Cell Biology)
Washington University in St. Louis, 2012
Professor Jean E. Schaffer, Chairperson

Accumulation of excess lipid in non-adipose tissues is associated with oxidative
stress and organ dysfunction and plays an important role in diabetic complications.
While a number of stress responses have been implicated, the precise molecular
mechanisms linking lipid accumulation and cellular dysfunction are not fully understood.
To elucidate molecular events critical for lipotoxicity, we used retroviral promoter trap
mutagenesis to generate mutant Chinese hamster ovary cell lines resistant to lipotoxic
and oxidative stress. This approach uncovered a previously unsuspected role for small
nucleolar RNAs (snoRNAs) as critical mediators of lipotoxic cell death.
Herein we show that under lipotoxic conditions, intronic snoRNAs in the rpL13a
gene accumulate in the cytosol during metabolic stress, suggesting that these noncoding RNAs function non-canonically to target cytosolic RNAs. Moreover, we
demonstrate that the rpL13a snoRNAs play a critical role in vivo in amplification of
reactive oxygen species and downstream oxidative stress-mediated tissue injury.
Study of independent mutants from our genetic screen not only identified a role
for snoRNAs in lipotoxicity, but also provided new insights into the cellular machinery for
xii

production of these non-coding RNAs. We demonstrate that the spliceosomal protein
SmD3 plays a critical role in expression of intronic non-coding RNAs, including the
rpL13a snoRNAs, by maintaining the abundance of snoRNA-containing intron lariats
from which they are processed. Our findings indicate that this function may involve
effects of SmD3 on small nuclear RNAs (snRNAs) U4 and U5.
Finally, we demonstrate a link between superoxide induction and cytosolic
snoRNA accumulation. Under lipotoxic conditions, superoxide induction precedes
cytosolic snoRNA accumulation. Other chemical inducers of superoxide also cause the
rpL13a snoRNAs to localize to the cytosol, and manipulation of superoxide dismutase
demonstrates that superoxide levels directly correlate with cytosolic snoRNA
expression.
Together, our studies identify an important role for snoRNAs in metabolic stress
responses. The rpL13a snoRNAs are essential for cell death in response to lipid
overload through functions that are distinct from their canonical role in ribosomal RNA
modification in the nucleolus. Moreover, these non-coding RNAs respond to chemical
inducers of reactive oxygen species and thereby may contribute more broadly to
disease pathogenesis that involves oxidative stress.
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CHAPTER 1
Introduction to Lipotoxicity

Type 2 diabetes is a growing worldwide health concern
Metabolic syndrome, obesity, and type 2 diabetes are growing in prevalence at
an astounding rate in the United States and around the world. Occurrence of type 2
diabetes is increasing in both adult and juvenile populations. In 2011, the Centers for
Disease Control estimated that 26 million Americans have type 2 diabetes and 79
million have some form of metabolic syndrome, and those numbers are expected to
double or triple by 2050 (National Diabetes Fact sheet 2011, online). Type 2 diabetics
have increased risks for heart disease, stroke, hypertension, nephropathy, neuropathy,
and retinopathy. In the United States, diabetes costs $174 billion annually, including
$116 billion in direct medical expenses. Therefore, it is becoming increasingly important
to understand the underlying causes of complications associated with diabetes.

Lipotoxicity is a hallmark of metabolic disease
Diabetes complications are likely related to the systemic metabolic abnormalities
in this disease. While it is well appreciated that hyperglycemia contributes to diabetes
pathogenesis, elevations in serum triglycerides and free fatty acids also play an
important role in the pathogenesis of diabetic complications. Under physiological
conditions, mammalian adipose cells internalize and store large quantities of lipid.
However, under pathophysiological conditions, accumulation of fatty acids in nonadipose tissues causes cell dysfunction and cell death that lead to impaired organ
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function (112). This phenomenon, known as lipotoxicity, contributes to the pathogenesis
of heart failure, renal dysfunction, steatohepatitis, and progressive pancreatic
insufficiency (3, 46, 50, 96, 97).

Mechanisms linking lipid overload to cell death
In vitro models in which the media of cultured cells is supplemented with excess
fatty acid have been used to probe metabolic and signaling pathways involved in the
cellular response to lipid overload. In a time- and dose-dependent manner, long-chain
saturated fatty acids induce apoptosis in a variety of cell types (11, 18, 61, 66, 124), and
this response is enhanced by high glucose (20). Although lipid overload in non-adipose
cells is initially buffered by cytoprotective triglyceride stores (60, 63), when the limited
capacity for neutral lipid storage in non-adipose cells is exceeded, excess saturated
fatty acids initiate several cellular stress response pathways. Fatty acid-induced
endoplasmic reticulum stress can result in reactive oxygen species (ROS) generation
(99). Independently, oxidative stress is induced in a variety of cell types through
activation of NADPH oxidase, mitochondrial dysfunction due to remodeling of organelle
membranes, and excessive cycles of oxidative phosphorylation (45, 82, 101). NADPH
oxidase participates in palmitate-induced superoxide production (31) and is likely to
spark a cascade of ROS production as ROS are rapidly interconverted (34).
Dismutation of superoxide produces hydrogen peroxide. Subsequently, hydrogen
peroxide will produce highly reactive hydroxyl radicals in the presence of metal ions
through Fenton or Harber-Weiss reactions. Hydrogen peroxide can also be converted to
hypochlorous acid in the presence of myeloperoxidase. Superoxide can also react with
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nitric oxide to form another highly reactive molecule, peroxynitrite. Excessive ROS lead
to detrimental consequences including protein carbonylation, lipid peroxidation, and
DNA damage (14, 17, 76). Administration of antioxidants to cultured cells and animal
models of lipotoxicity mitigates against lipotoxic cell death (8, 9, 56, 61), suggesting a
central role for oxidative stress in lipotoxicity.

Elucidating molecular mechanisms of lipotoxicity
Despite identification of stress pathways involved in lipotoxicity, the precise
molecular responses following lipid overload have yet to be elucidated. To identify
genes critical for the cellular lipotoxic response, we performed a genetic screen in
Chinese hamster ovary (CHO) cells, with mutagenesis by transduction with ROSAβgeo
retrovirus at low multiplicity of infection to achieve, on average, one insertion per ten
genomes. Although the integrated provirus contains a cDNA cassette for a βgalactosidase-neomycin phosphotransferase fusion protein, it lacks its own promoter,
and thus its transcript is expressed only if the retrovirus inserts downstream of an active
promoter and splice donor site. Mutagenized cells that survived a round of neomycin
selection were then treated for 48 h in media supplemented with a lipotoxic
concentration of palmitate (500 µM) to model pathophysiological states. Under these
conditions, wild type (WT) cells were killed, but mutant cells, each with a single
disrupted gene critical for lipotoxicity, survived.
This genetic screen led to the identification of many unpredicted genes as
essential for the lipotoxic response. The eukaryotic elongation factor (eEF) 1A-1 was
shown to have a role in ROS and ER stress induced death (7). The non-coding RNA
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gadd7 was shown to be induced by lipotoxic stress in a ROS-dependent fashion and
drive ROS propagation following palmitate treatment, demonstrating that gadd7
functions as a feed-forward regulator of lipid-induced and ROS-induced cell death (9). In
another mutant cell line (6F2), the promoter trap disrupted the locus for ribosomal
protein L13a (rpL13a) (72). Studies of this mutant revealed that the portions of this gene
essential for lipotoxicity are three highly conserved small nucleolar RNAs (snoRNAs)
embedded within the rpL13a introns, rather than the protein-coding exonic sequences.
These findings suggest a previously unsuspected role for snoRNAs in the regulation of
metabolic stress in mammalian cells.

Conserved functions of snoRNAs
SnoRNAs are typically nucleolar-localized RNAs that guide the modification of
other non-coding RNAs (ncRNAs). Eukaryotic cells contain more than 200 unique
snoRNAs comprised of two families—the box C/D snoRNAs and box H/ACA snoRNAs
(57). The vast majority of snoRNAs transiently base pair with complementary target
RNA to guide either 2’-O-methylation (C/D snoRNAs) or pseudouridylation (H/ACA
snoRNAs) of target RNA (69). These modifications are the most common covalent
modifications found in ribosomal RNA (rRNA) and are found in key regions of rRNA
including the peptidyl transferase center and the mRNA-decoding center. Both types of
modifications are essential for ribosome function, and the importance of these
modifications is emphasized by the evolutionary conservation of modification locations.
Other snoRNA modification targets include snRNAs in eukaryotes, transfer RNAs in
archaea, and spliced leader RNAs in trypanosomes (16, 19, 111). Spliceosome function

4

also depends on the modification of snRNAs by C/D and H/ACA snoRNAs. Modification
of snRNAs takes place in Cajal bodies providing evidence for extranucleolar roles for
snoRNAs (16). The precise function of modified nucleotides in rRNAs and snRNAs
remains unknown, but they are hypothesized to have a critical function, since complete
loss of modification causes lethality and specific mutations can cause disease (15). 	
  
Both snoRNA families are structurally and functionally conserved from humans to
Archaea (77, 104, 105). Box C/D snoRNAs contain the conserved sequence motifs
UGAUGA (C box) and CUGA (D box) near the 5’ and 3’ ends of the snoRNA,
respectively. The two boxes are separated by ~60nt and internal C’ and D’ boxes are
often present in that region. Base-pairing to target RNAs typically takes place in the
region directly upstream of the D box or D’ box, involving a sequence known as the
antisense element (Figure 1.2) Box C/D snoRNAs are associated with four box C/D
snoRNP proteins, fibrillarin, Nop56, Nop58, and 15.5K/NHPX (55, 74, 93, 107, 123,
127). Fibrillarin catalyzes the 2′-O-methyl transfer at the site determined by the box C/D
snoRNA guide (118)
Similarly, H/ACA snoRNAs are characterized by a conserved secondary
structure. Each H/ACA snoRNA is defined by a hairpin–hinge–hairpin–tail structure with
two short conserved sequences called boxes H and ACA. One or both hairpins have an
internal loop with two short sequences that are complementary to the rRNA substrate.
These pseudouridylation pockets enable anti-sense base-pairing with target RNAs in
the region where they direct modifications (Figure 1.2). The box H/ACA snoRNAs form
snoRNP complexes with dyskerin, Nhp2, Nop10, and Gar1 proteins (4, 29, 35, 65, 120).
The enzyme responsible for uridine-to-pseudouridine isomerization is dyskerin (39). 	
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Palmitate treatment induces rpL13a snoRNA accumulation in CHO cells.
Identification of the snoRNA encoding rpL13a locus through the genetic screen
conducted in the Schaffer Lab suggested snoRNAs have a role in lipotoxicity. All
mammalian loci for rpL13a contain four highly conserved intronic box C/D snoRNAs that
are processed during splicing of the rpL13a pre-mRNA transcript (Figure 1.3A) (75).
These snoRNAs, U32a, U33, U34, and U35a, are encoded within introns 2, 4, 5 and 6,
respectively, and range in size from 61-82 nucleotides. U32a, U33, U34, and U35a are
highly conserved across species.
Lipotoxic conditions induce the pre-mRNA expression of many genes including
rpL13a. Consistent with up-regulation of the pre-mRNA, rpL13a snoRNAs also
accumulate under stress conditions as assessed by RNase protection assays with

32

P-

labeled probes specific for the snoRNA sequences (Figure 1.3B & C). In comparison,
levels of the microRNA miR-16 do not change under these conditions. In WT CHO cells,
U32a, U33, and U35a snoRNAs are expressed at low levels under basal conditions and
increased following palmitate treatment, whereas U34 is not detected under basal or
lipotoxic conditions. In mutant 6F2 cells, induction of U32a, U33, and U35a is markedly
attenuated, consistent with disruption of the rpL13a locus (Figure 1.3B & C). Palmitate
induction of U32a, U33, and U35a snoRNAs is also observed in WT C2C12 murine
myoblasts, which demonstrate similar sensitivity to lipotoxic conditions (72). Moreover,
these snoRNAs are induced by saturated fatty acids known to cause lipotoxicity
(myristic, palmitic, and stearic acids), but not by unsaturated palmitoleic acid and oleic
acid, which are well tolerated by cells. These findings suggest a conserved role for
snoRNAs as mediators of lipotoxicity.
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Confirmation of the role for rpL13a snoRNAs in lipotoxicity.
Demonstration of rpL13a snoRNAs as mediators of metabolic stress was
confirmed in two ways (72). First, stable cell lines generated in the mutant 6F2
background showed that snoRNA sequences within the rpL13a genomic locus are
required for complementation of 6F2 cells. Mutant cells transfected with a plasmid
containing 4.3 kb from the murine rpL13a genomic locus, including all eight exons and
intervening introns, restored palmitate-induced snoRNA expression, palmitate-induced
ROS, and palmitate-induced cell death. By contrast, when mutant cells were transfected
with a similar construct in which all four snoRNAs were removed, but promoter and
exon-intron structure was otherwise intact, complementation was lost. In an alternate
approach to genetic confirmation, simultaneous knock-down of U32a, U33, and U35a in
wild-type murine myoblasts by nucleofection with phosphorothioate-modified anti-sense
oligos (ASOs) rendered these cells resistant to palmitate-induced ROS and cell death.
Since loss of a single snoRNA alone did not recapitulate lipotoxicity resistance, these
data support a model in which the three snoRNAs function in concert to promote
palmitate-induced oxidative stress.

Biogenesis of box C/D and H/ACA snoRNPs
The ability of the rpL13a locus to regulate oxidative stress is dependent on
expression of the encoded snoRNAs, which are presumed to form small nucleolar
ribonucleoproteins (snoRNPs). Biogenesis of box C/D and H/ACA snoRNPs is a highly
regulated, multi-step process initiated during the transcription of a snoRNA host gene.
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In vertebrates, the vast majority of box C/D and H/ACA snoRNAs are encoded within
introns of pre-mRNAs (25, 52, 58, 108, 109). All host introns for vertebrate snoRNAs
encode only a single intronic snoRNA. During splicing, snoRNAs are excised from the
pre-mRNA as part of the intron lariat. Mammalian pre-mRNA intron lariats are rapidly
debranched and degraded after splicing (83). 5’ to 3’ and 3’ to 5’ exonucleases recycle
the linearized intron lariat (79). Active recruitment of snoRNP proteins to the nascent
snoRNA during synthesis and/or splicing of the host pre-mRNA is required for efficient
intronic snoRNP production. The associated snoRNP proteins define the termini of the
snoRNA by protecting them from the processing exonucleases (13, 51, 108, 122).
Following trimming of the flanking intron, the mature snoRNP is released.
Biosynthesis of functional box C/D snoRNPs requires the ordered recruitment of
snoRNP proteins 15.5K/NHPX, Nop56, Nop58, and fibrillarin. To establish a scaffold for
the 15.5K/NHPX snoRNP protein, a functional Kink-turn structure must be formed by
the nascent snoRNA. The 5’ and 3’ box C and D terminal regions of the snoRNA form
this Kink-turn by folding into a stem-internal loop-stem structure (54, 123). Conserved
nucleotides in the C and D box motifs form non-canonical G-A, A-G, and U-U base pairs
establishing the Kink-turn and docking site for the 15.5K/NHPX protein. Binding of
15.5K/NHPX induces a sharp bend in the phosphodiester backbone of the two
contiguous RNA stems of the Kink-turn (102, 103, 115, 119). This conformational
change provides the structural requirements for the subsequent binding of Nop58,
Nop56, and two copies of fibrillarin (12). One fibrillarin and Nop58 bind to the box D and
C sequences in the upper stem of the Kink-turn. Nop56 and another copy of fibrillarin
bind to the internal C’ and D’ boxes.
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Position within the intron is also critical for efficient processing of human box C/D
snoRNAs. Most box C/D snoRNAs are located about 80-90 nucleotides upstream of the
3’ splice site (38). An optimal distance of ~50 nucleotides between the snoRNA coding
region and the branch point of the host intron is required for efficient snoRNA
processing. Increasing or decreasing the length between the snoRNA and the branch
point significantly compromises snoRNA accumulation (37). The relationship between
snoRNA location and the branch site suggests there is a synergy between intronic
snoRNA processing and pre-mRNA splicing. Consistent with a splicing-depending
mechanism for box C/D snoRNA processing, 15.5K/NHPX is recruited to box C/D
intronic snoRNAs at the C1 splicing complex stage. A general splicing factor, intron
binding protein 160 (IBP160), provides a molecular link between the spliceosome and
the nascent box C/D snoRNA (36). IBP160 has putative helicase activity and is thought
to trigger box C/D snoRNP assembly by interacting with the U2 spliceosomal small
nuclear RNP (snRNP) or other splicing factors associated with the branch-point region
in the C1 splicing complex.	
  
Box H/ACA snoRNPs also require ordered recruitment of snoRNP proteins.
However, in contrast to box C/D snoRNAs, human H/ACA snoRNAs have no
preferential intronic location relative to the 5’ or 3’ splice sites of the host introns (88,
92). Human box H/ACA snoRNAs are commonly found in introns of longer than average
length. H/ACA snoRNAs are also processed efficiently from artificial host pre-mRNAs
regardless of position within the intron suggesting that box H/ACA snoRNAs are
processed independent of relative splice site location (88).
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Many class specific factors regulate the biogenesis of box C/D snoRNAs and box
H/ACA snoRNAs, but the excision of all intronic snoRNPs requires splicing. The
relationship between pre-mRNA splicing and snoRNA biogenesis suggests the
spliceosomal machinery is critical for snoRNA expression. The spliceosome is a
complex RNA machine comprised of its own set of ncRNAs, the small nuclear RNAs
(snRNAs), and over 100 proteins (117). Each snRNA is bound to a unique set of
proteins to form a small nuclear ribonucleoprotein (snRNP). In addition to snRNPspecific proteins, each of the major snRNAs (U1, U2, U4, and U5) is bound to a
common set of seven proteins (SmB/B’, SmD1, SmD2, SmD3, SmE, SmF, and SmG).
These proteins form a seven-membered ring around the short, highly conserved,
uridine-rich sequence on each snRNA called the Sm site (1, 47, 100). Assembly of Sm
cores onto snRNAs is regulated by the SMN complex (22, 71, 84). Following assembly
of the Sm protein heptameric ring, the 5’ cap of the snRNA is hypermethylated to form
the 2,2,7-trimethyl guanosine cap, and the mature snRNP is then imported into the
nucleus by snurportin and importin β for final association with snRNP-specific proteins
and utilization in mRNA splicing (23, 24, 42, 70, 86).

Summary
Herein, we describe work that provides new understanding of the function of the
rpL13a snoRNAs in cells and in a rodent model of acute oxidative stress, identifies a
role for the spliceosomal protein, SmD3, in regulating the biogenesis of intronic ncRNAs
including the rpL13a snoRNAs, and uncovers a link between superoxide production and

10

induction of the rpL13a snoRNAs. Together, our studies provide important new insights
into the production and function of snoRNAs during metabolic stress.
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Figure 1.1	
  

	
  
	
  
Figure 1.1 Genetic screen to isolate palmitate resistant CHO mutants. Wild type
(WT) CHO cells were transduced with the ROSAβgeo retrovirus, leading to integration
of the provirus containing a splice acceptor, promoterless β-galactosidase-neomycin
resistance cassette, and polyadenylation sequences. Promoter-trapping and gene
disruption at the site of integration was selected for by growth in neomycin (NEO), and
palmitate-resistant mutants were selected by growth in media with 500 µM palmitate
(palm) for 48 h.
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Figure 1.2

A

B

Figure 1.2 Secondary structure of box C/D and box H/ACA snoRNAs. A) Box C/D
snoRNAs (green) are characterized by box C and D motifs. Sequences upstream of box
D and D’ base pair (blue) with target RNAs (red) to guide the 2’-O-methylation of target
RNA. B) Box H/ACA snoRNAs are characterized a hairpin–hinge–hairpin–tail structure
and box H and ACA motifs. Pseudouridylation pockets allow for base pairing with target
RNAs to guide pseudouridylation modifications.
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Figure 1.3

A
ROSA geo

rpL13a genomic
U32a

B

U33

U34 U35a

C
U32a

snoRNA: miR-16
(rel units)

8

U33
U34
U35a
miR-16
palmitate

6
4

- +

WT

6F2

*

2
0

- +

U32a
U33
U35a

UT

Palm

UT

Palm
6F2

WT

Michel CI et al. 2011 Cell Metab

Figure 1.3 rpL13a-encoded box C/D snoRNAs are induced in palmitate treated
CHO cells. (A)	
   rpL13a gene organization showing location of ROSAβgeo promoter trap
insertion and locations of intronic U32a, U33, U34, and U35a snoRNAs. (B, C) WT and
6F2 cells were untreated (UT) or supplemented with palmitate for 48 h. (B) Small RNA
was harvested and used in RNase protection assay with

32

P-labeled hamster rpL13a

snoRNA probes or miR-16 probe as control. (C) Autoradiograms from RNase protection
experiments as in (B) were quantified by densitometry. All data expressed as mean ±
SE for 3 independent experiments. * p < 0.01 for palmitate treated vs. untreated.
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CHAPTER TWO
rpL13a snoRNAs function as non-canonical box C/D snoRNAs

INTRODUCTION
Box C/D snoRNAs U32a, U33, and U35a are critical for the propagation of ROS
following lipid overload in cultured cells (72). The mechanisms through which rpL13a
snoRNAs recognize metabolic stress and regulate the cellular stress response remain
unclear. Typically, box C/D snoRNAs serve as guides for ribonucleoprotein particles
during 2’-O-methylation of rRNA. These modifications occur within the nucleolus, where
the vast majority of snoRNAs reside. Extranucleolar functions for snoRNAs have also
been described. SnoRNAs are known to traffic to Cajal bodies where they can serve to
guide the modification of snRNAs (16). Recent studies have suggested a number of
additional non-canonical roles for snoRNAs. A brain specific snoRNA, HBII-52, has
been shown to interact with a pre-mRNA in the nucleoplasm and play a role in
alternative splicing (49). Biochemical and computational analyses from multiple groups
show snoRNAs can be processed into miRNAs in a Dicer dependent fashion,
suggesting snoRNAs may localize to the cytoplasm where processing and function
would take place (21, 78, 90). Additional snoRNAs have been identified or
computationally predicted to lack rRNA or snRNA antisense homology (43). These
“orphan” snoRNAs could serve as guides for currently unidentified target RNAs in
unknown locations.
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Here, we extend the initial finding that rpL13a snoRNAs are critical mediators of
metabolic stress by examining their role in vivo. We demonstrate that U32a, U33, and
U35a contribute to oxidative stress and oxidative damage in a mouse model of
inflammation and oxidative stress. Furthermore, we broaden our understanding of
snoRNA function in the metabolic stress pathway in several ways. By examining
predicted rpL13a modification sites in 6F2 cells, we show that methylation of these
rRNA nucleotides is not affected by altered levels of the snoRNAs during lipotoxicity. By
characterizing the localization of rpL13a snoRNAs in wild type cells, we show that they
accumulate in the cytoplasm during lipotoxicity. This novel localization for intronencoded snoRNAs provides insight into the potential mechanism through which rpL13a
snoRNAs regulate oxidative stress.

RESULTS
In vivo expression of rpL13a snoRNAs. Our studies of the rpL13a snoRNAs show
that these molecules function in the cellular response to lipotoxic and oxidative stress.
To extend these findings to an in vivo model of oxidative stress, we examined the
expression of rpL13a snoRNAs in a well-established model of lipopolysaccharide (LPS)mediated liver injury that is characterized by inflammation, steatosis, and oxidative
stress (5). Compared to saline-injected control mice, liver tissue from LPS-treated mice
showed significant up-regulation of cytosolic U32a, U33, and U35a snoRNAs (Figure
2.1), demonstrating that the rpL13a snoRNAs are induced in vivo in response to
metabolic stress.
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In vivo rpL13a snoRNA knockdown reduces oxidative damage. Based on these
findings, we analyzed the effects of loss-of-function of the rpL13a snoRNAs in the LPSmediated liver injury model. To achieve specific knockdown of the snoRNAs in vivo,
prior to LPS injection, mice were treated with three serial intraperitoneal injections of
antisense locked nucleic acid oligonucleotides directed against each of the three
snoRNAs or directed against GFP as a control. Antisense oligonucleotides directed
against the snoRNAs achieved 72, 84, and 74% knockdown of U32a, U33, and U35a,
respectively, in liver tissue following LPS injection without diminishing LPS-induced
inflammation (Figure 2.2). Knockdown of the snoRNAs mitigated LPS-induced oxidative
stress in the liver as demonstrated by dihydroethidium staining for superoxide and
oxidative damage to liver tissue proteins and lipids (Figures 2.3 and 2.4). These findings
indicate that rpL13a snoRNAs are required in vivo for propagation of oxidative stress.

rpL13a guided rRNA modifications are unaltered during lipotoxicity. Canonical box
C/D snoRNAs participate in ribonucleoproteins that localize to nucleoli. In S. cerevisiae
and in X. laevis, box C/D snoRNAs serve as guides that target 2’-O-methylation of
rRNAs with which they share short stretches of antisense homology (53). Although they
lack some sequence features of canonical 2’-O-methylation guide snoRNAs (internal
box C’ sequence not well-conserved, U33 lacks box D’, rRNA complementarity not
upstream of box D in U35a), U32a, U33, and U35a each contain 10-12 nucleotide
stretches of complementarity to rRNA sites of 2’-O-methylation (Figure 2.5), suggesting
a potential role as guide RNAs for 2’-O-methylation of G1328 in 18S and A1511 in 28S
(U32a), U1326 in 18S (U33), and C4506 in 28S (U35a) rRNAs (75). We reasoned that if
the mechanism of action of snoRNAs U32a, U33, and U35a in lipotoxic and oxidative
17

stress involved 2’-O-methylation of these rRNAs, modifications of these rRNA sites
should be diminished in 6F2 compared to WT cells under metabolic stress conditions
when the snoRNAs are induced in WT cells. However, primer extension studies showed
no differences in the extent of modification of these rRNA sites between WT and 6F2
cells under basal or palmitate-treated conditions (Figure 2.6). These data indicate that
under basal and lipotoxic conditions, either residual expression of U32a, U33, and U35a
in 6F2 cells is sufficient to support these modifications of rRNAs, or this function is
subserved by other molecules in eukaryotic cells. Furthermore, at a point in the lipotoxic
response at which absence of snoRNA induction is readily apparent and functionally
correlates with resistance to lipotoxicity in 6F2 cells, there is no corresponding change
in 2’-O-methylation of rRNAs.

rpL13a

snoRNAs

accumulate

in

the

cytoplasm

during

lipotoxicity. We

hypothesized that if U32a, U33, and U35a were involved in functions other than
modification of ribosomal RNAs, then under lipotoxic stress conditions, they may have a
subcellular distribution distinct from canonical box C/D snoRNAs, which co-localize with
nascent rRNAs in the nucleolus. Following palmitate treatment of C2C12 cells, we
isolated nuclear and cytosolic RNAs by sequential detergent extraction and quantified
U32a, U33, and U35a by qRT-PCR. With palmitate treatment U32a, U33, and U35a
increase in the cytoplasm, whereas levels of these snoRNAs remain unchanged in the
nucleus (Figure 2.7A and B). Accumulation of rpL13a snoRNAs in the cytosol under
lipotoxic conditions was confirmed by fluorescence in situ hybridization. As expected,
anti-sense probe for snoRNA U3 demonstrated strong nucleolar localization, and this
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was unaffected by lipotoxic stress (Figure 2.8A). Staining for the rpL13a snoRNAs was
performed in cells nucleofected with control ASO (GFP) or with ASO targeting each of
the rpL13a snoRNAs to ascertain the specificity of signal. Consistent with data from
RNase protection and qPCR assays, in control nucleofected cells expression of U32a,
U33, and U35a was low under normal growth conditions and increased under lipotoxic
conditions (Figure 2.8B, GFP-nucleofected panels). Prominent staining for each of
these snoRNAs was observed in the cytoplasm, but not nucleoli. The probe for U32a
also stains non-nucleolar regions of the nucleus. Cytoplasmic staining for the rpL13a
snoRNAs under lipotoxic conditions was markedly diminished when the snoRNAs were
depleted by specific ASOs that target each snoRNA (Figure 2.8B, U32a, U33, and U35a
ASO-nucleofected panels). Cytoplasmic staining for U32a, U33, and U35a was also
distinct from the nuclear pattern observed under lipotoxic conditions using a probe
specific for intron 1 (Figure 2.8A), indicating that the cytosolic distributions of the rpL13a
snoRNAs do not simply reflect localization of the pre-mRNA. The nuclear staining for
U32a resembled the staining for intron 1 and was not diminished with ASOs that target
U32a, suggesting that this represents detection of the pre-mRNA, which is not targeted
by U32a ASOs. Together our biochemical and in situ hybridization data support a model
in which U32a, U33, and U35a snoRNAs act in non-canonical roles in the cytoplasm
during lipotoxic stress.

CONCLUSIONS
SnoRNAs U32a, U33, and U35a are critical for the cellular response to metabolic
stress. In vivo knockdown of these three snoRNAs further illustrates their importance to
the pathophysiology of metabolic stress. The LPS-induced model of hepatic tissue injury
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confirms that the rpL13a snoRNAs are induced in the setting of oxidative stress in vivo.
Moreover, our in vivo knockdown data show that these snoRNAs are required for
amplification of oxidative stress and for propagation of oxidative stress-mediated
damage to proteins and lipids. Because LPS has pleiotropic effects in vivo and because
ASO knockdown in vivo is limited by liver toxicity, it is not surprising that in vivo
knockdown of these snoRNAs provided only a partial reduction in the oxidative stress
response and did not blunt the release of serum transaminases into the circulation (not
shown). In future studies, genetic approaches to loss of function and/or blunting of
additional effector pathways (e.g., inflammatory signaling) may be required to block liver
injury entirely. Nonetheless, our in vivo knockdown studies show that the rpL13a
snoRNAs are required for the full induction of tissue oxidative stress in the murine LPS
model, thus providing in vivo evidence for a role of snoRNAs in metabolic stress.
We show here in a stable mutant cell line that decreased basal expression of
U32a, U33, and U35a snoRNAs and loss of palmitate induction of these snoRNAs is not
associated with changes in 2’-O-methylation of predicted rRNA targets, yet is
associated with resistance to lipotoxicity. While it is possible that these snoRNAs
contain more than one functional guide sequence to target multiple substrates including
rRNAs (13, 110), their accumulation in the cytosol during lipotoxicity suggests a nonnucleolar function for these snoRNAs. Movement of snoRNAs to the cytosol is not
without precedent, since the independently transcribed box C/D snoRNA, U8, has been
shown to be exported from the nucleus (121). Here, we provide the first direct evidence
that intronic snoRNAs can also localize to the cytosol. Our data are most consistent with
a model in which the rpL13a snoRNAs function in lipotoxicity and oxidative stress
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response pathways as non-canonical box C/D snoRNAs. Furthermore our findings
suggest that the rpL13a snoRNAs affect targets in the cytoplasm.
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Figure 2.1 In vivo expression of rpL13a snoRNAs. (A) Mice were injected
intraperitoneally with lipopolysaccharide (LPS), or equivalent volume of phosphatebuffered saline (PBS) as control, and liver tissue was harvested 12 h later. Cytosolic
RNA isolated from livers was used for quantification of rpL13a snoRNAs (relative to
36B4) or iNOS and Cox2 (relative to actin). Graph shows mean ± SE from a
representative experiment with N = 3 (PBS) and N = 4 (LPS) animals per group. * p <
0.05 for LPS vs. PBS.
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Figure 2.2 ASO knockdown of rpL13a snoRNAs in vivo. Mice were pretreated with
three serial doses of ASOs targeting rpL13a snoRNAs or GFP as control prior to LPS
injection and analysis of liver tissue. snoRNA, iNOS, and Cox2 expression in liver
cytosol was quantified as in Figure 2.3. n = 4 to 6 per group.
* p < 0.05 for GFP vs. snoRNA knockdown.
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Figure 2.3
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Figure 2.3 rpL13a snoRNAs are required for oxidative stress in vivo. Mice were
pretreated with three serial doses of ASOs targeting rpL13a snoRNAs or GFP as control
prior to LPS injection and analysis of liver tissue. Representative images show frozen
sections of liver tissue stained with DHE and parallel sections in which staining was
performed in the presence of pegylated superoxide dismutase (SOD) as control. Scale
bar, 100 µm. Graph shows quantification of fluorescence intensity. n = 4 to 6 per group.
* p < 0.05 for GFP vs. snoRNA knockdown.
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Figure 2.4
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Figure 2.4 In vivo rpL13a snoRNA knockdown reduces oxidative damage. Mice
were pretreated with three serial doses of ASOs targeting rpL13a snoRNAs or GFP as
control prior to LPS injection and analysis of liver tissue. Quantification of (A) protein
carbonylation by western blotting and (B) tissue oxysterols (7-ketocholesterol, 7-keto;
3β,5α,6β-cholestantriol, triol) 24 h following LPS. n = 4 to 6 per group. * p < 0.05 for
GFP vs. snoRNA knockdown.
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Figure 2.5
U32a
Mm GAgtcCAtgatgagcaacaCtcaccatctttcgtttgagtctcacgAcTGtgagatcaa-cccatgcaccgctctgagacTC
Cg AAgtcAGtgatgagcaacaAtcaccatctttcgtttgagtctcacgAcTGtgagatcaa-cccatgcaccgctctgagacTT
Hs AGgtcAGtgatgagcaacaTtcaccatctttcgtttgagtctcacgGcCAtgagatcaaCcccatgcaccgctctgagacCT
U33
Mm cAgcTTGtgatgagA-c-AtctcccactCATGttcgagttGcTcGacTatgagaTGactcTacatgcactaccatctgaggcTGT
Cg cAgcCTAtgatgaAG-cGAtctcccactGGTGttcgagttTcCcAacTatgagaCAactcTacatgcactaccatctgaggcTGG
Hs cGgcCGGtgatgagAAc-TtctcccactCACAttcgagttTcCcGacCatgagaTGactcCacatgcactaccatctgaggcCAC
U34
Mm cgtcTGtgatgttcTgcTaTtacctacattgtttgaGcctcatgaaaAcCCcactGgctgagacgc
Cg cgtcTGtgatgttcTgcTaTtacctacattgtttgaGcctcatgaaaAcGCcactAgctgagacgc
Hs cgtcCAtgatgttcCgcAaCtacctacattgtttgaTcctcatgaaaGcAGcactGgctgagacgc
U35a
Mm ggcaCatgatgtTCttatTctcacgatggtctTcggatgCcAcAgTTAGgGCaGtgCcgaTaatgccaAAggctAagctgatgccagGa
Cg ggcaGatgatgtTTttTtTctcacgatggtctTcggatgCcAcCgATTGg-CaGtgCcgaTaatgccaCAggctCagctgatgccagTa
Hs ggcaGatgatgtCCttat-ctcacgatggtctGcggatgTcCcTgT---gGGaAtgGcgaCaatgccaATggctTagctgatgccagGa

box C

box D'

box D
From Michel et al. 2011

Figure 2.5 U32a, U33, and U35a contain antisense homology to rRNA. Comparison
of rpL13a snoRNA sequences from mouse (Mm), hamster (Cg), and human (Hs)
species. C, D, and D’ box sequences are indicated in boxed bolded text. Regions with
antisense homology are underlined. Conserved and non-conserved nucleotides are
displayed in lower and upper case letters, respectively.
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Figure 2.6
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Figure 2.6 2’-O-methylation is unaffected in 6F2 cells. WT and 6F2 cells were
treated with 500 µM palmitate and total RNA analyzed for pseudouridylation or 2’-Omethylation nucleotide modification of predicted sites using reverse transcriptase primer
extension. Autoradiograms show primer extension assays and parallel sequencing for
detection of (A) U32a and U33 target sites on 18S rRNA (G1328 and U1326,
respectively); (B) U32a target site on 28S rRNA (A1511); (C) U35a target site on 28S
rRNA (C5406); (D) unrelated snoRNA target sites on 18S rRNA as controls (snoRNAs
Z17a & Z17b target U121; snoRNAs U45a & U45c target A159). For each panel, arrows
point to bases in rRNA (numbered according to human rRNA sequence) that are
modified and corresponding DNA sequence is shown in the left-most four lanes.
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Figure 2.7
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Figure 2.7 rpL13a snoRNAs accumulate in the cytoplasm under lipotoxic
conditions. (A, B) C2C12 cells were untreated (UT) or treated with palmitate for 24 h.
Cells were separated into cytosolic (CYT) and nuclear (NUC) fractions by sequential
detergent solubilization. (A) Fractions were analyzed by western blotting for a cytosolic
marker, hsp90, and for a nuclear marker, lamin B1. (B) Total RNA was prepared from
the fractions and analyzed for rpL13a snoRNA abundance relative to 36B4 by qRTPCR. Graphs show mean ± SE from a representative experiment (n = 3). * p < 0.05 for
palmitate treated vs. UT.
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Figure 2.8
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Figure 2.8 rpL13a snoRNAs accumulate in the cytoplasm under lipotoxic
conditions. (A, B) C2C12 cells were analyzed by in situ hybridization under basal
conditions (UT) and following 24 h treatment with palmitate (PALM) using specific
snoRNA or control probes (red). Nuclei were stained with SYTOX Green. (A) Cells were
probed with U3 antisense probe for known nucleolar snoRNA, control U3 sense probe,
and control rpL13a intron 1 antisense probe. (B) Control GFP ASO-nucleofected and
specific snoRNA ASO-nucleofected cells were examined by in situ hybridization with
antisense probes for U32a, U33, and U35a. Bars, 10 µm.
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CHAPTER THREE
SmD3 regulates intronic snoRNA biogenesis

INTRODUCTION
Most vertebrate snoRNAs are encoded within introns and co-transcribed with
their host genes (109). Intronic box C/D snoRNP protein assembly initiates during the
C1 complex stage of splicing (37), with subsequent intron lariat formation at the C2
complex stage of splicing followed by debranching and exonucleolytic trimming of the
mature snoRNP (51, 80, 85). The observations that rpL13a snoRNAs rapidly
accumulate in the cytosol during metabolic stress and are required for lipotoxic cell
death suggest that cytoplasmic RNAs may be their primary targets and that efficient
processing of these intronic elements is important for the lipotoxic response. However,
the precise molecular mechanisms through which snoRNAs are induced and regulated
during lipotoxicity remain to be elucidated.
Our genetic screen led to isolation of a second, independent mutant cell line
harboring a disruption in an RNA-related gene. This novel mutant cell line is
haploinsufficient for SmD3, a core component of the spliceosome. We demonstrate that
SmD3 participates in the lipotoxic response through regulation of intron lariat
abundance and biogenesis of intron-encoded rpL13a snoRNAs. We also provide
evidence linking the expression of SmD3 to the levels of critical snRNA components of
the spliceosome and generalized production of intronic non-coding RNAs (ncRNAs).
Our results extend the known function for SmD3 in splicing to a specific role within
individual snRNPs essential for the biogenesis of intronic ncRNAs.
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RESULTS
SmD3 haploinsufficiency confers resistance to palmitate-induced cell death. The
6H2 mutant cell line was isolated from our genetic screen for genes that are critical for
the lipotoxic response. To quantify the degree of palmitate resistance in mutant 6H2,
WT and 6H2 cells were treated with palmitate for 48 h, and cell death was quantified by
propidium iodide (PI) staining and flow cytometric analysis. Compared to WT cells, 6H2
cells were significantly protected from palmitate-induced death (Figure 3.1A). By
contrast, treatment of WT and 6H2 cells with the general apoptosis inducers
camptothecin, staurosporine, and actinomycin D revealed no differences in sensitivity.
Therefore, palmitate-resistant 6H2 cells are not generally resistant to cell death.
The promoter trap mutagenesis facilitated identification of the disrupted gene
because of the unique fusion transcript produced upon a single productive integration.
To confirm the presence of a single retroviral integration, Southern blot analysis of 6H2
genomic DNA was performed, probing for the ROSAβgeo sequence (Figure 3.2A). The
presence of a single hybridizing band in DNA digested with multiple different restriction
enzymes is consistent with a single retroviral integration. To identify the disrupted gene
in the mutant 6H2 cells, mRNA was isolated and used for 5’ rapid amplification of cDNA
ends (5’ RACE). Unique sequence from the RACE product was analyzed using NCBI
BLAST, which revealed that the site of integration was the snrpD3 gene encoding the
small nuclear ribonucleoprotein SmD3. SmD3 is a component of the spliceosome that,
together with other Sm family proteins, forms a heteroheptameric ring around snRNAs
U1, U2, U4, and U5 to generate small nuclear ribonucleoproteins (snRNPs) essential for
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the removal of introns from pre-mRNA (125). PCR was performed to confirm integration
of the ROSAβgeo sequence into snrpD3 (Figure 3.2B). Reactions with forward and
reverse primers designed to snrpD3 resulted in PCR products for both WT and 6H2
cDNA, indicating that each cell type maintains at least one intact allele. As expected, no
product was detectable in WT cells when snrpD3 forward and ROSAβgeo reverse
primers were used, but this set of primers produced the expected PCR product from the
fusion transcript in 6H2 cells. These PCR results confirm our 5’ RACE identification of
the disrupted gene and suggest that 6H2 cells are haploinsufficient for snrpD3.
Consistent with this model, quantitative real-time PCR (qRT-PCR) revealed a ~50%
reduction in relative snrpD3 mRNA (Figure 3.2C) and western blotting revealed a
corresponding ~50% reduction of SmD3 protein (doublet at 15 kDa and 18 kDa) in 6H2
relative to WT cells (Figure 3.2D). Thus, expression of snrpD3 in 6H2 cells is consistent
with a model in which integration of the ROSAβgeo provirus disrupted one of two alleles
for snrpD3.

Targeted knockdown of SmD3 recapitulates 6H2 phenotype. To confirm that the
palmitate-resistant phenotype in 6H2 cells is due to diminished SmD3 protein
expression, we used shRNA to knockdown SmD3 in WT CHO cells and tested for
associated changes in palmitate sensitivity. SmD3 protein levels were measured by
western blot following isolation of individual stable clonal knockdown lines. Two
independently isolated clonal lines showed 47% (sh1) and 64% (sh2) knockdown
relative to scrambled (contr) shRNA transfected cells (Figure 3.3A and 3.3B).
Knockdown clones were protected from palmitate-induced death as measured by PI

32

staining, and the degree of protection was proportional to the degree of knockdown
(Figure 3.3C). These data provide independent genetic evidence that loss-of-function of
SmD3 protects against lipotoxicity.

SmD3 disruption protects cells from generalized oxidative stress induction.
Lipotoxicity is known to involve fatty acid (FA) import and the generation of oxidative
stress (8, 60). To test whether 6H2 cells acquired resistance through diminished
capacity to take up palmitate, initial rates of FA uptake were quantified in WT and 6H2
cells. There was no significant difference between WT and 6H2 cells (Figure 3.4A),
indicating that resistance to lipotoxicity in 6H2 cells did not result from failure to take up
exogenous FA. To probe downstream aspects of the lipotoxic response, we quantified
palmitate-induced ROS in WT and 6H2 cells by CM-H2DCFDA (DCF) staining and flow
cytometric analysis. At 5 and 16 h following palmitate supplementation, ROS induction
was significantly blunted in 6H2 cells (Figure 3.4B). SmD3 knockdown clones were also
protected from palmitate-induced ROS (Figure 3.4C). More direct induction of oxidative
stress following exposure to H2O2 or menadione also resulted in blunted ROS levels in
6H2 cells compared to WT (Figure 3.4D), indicating 6H2 cells are protected not only
from palmitate-induced ROS but also from generalized oxidative stress induction or
amplification.

SmD3 regulates intronic non-coding RNA expression. The ROS resistance
phenotype observed in 6H2 cells is similar to the previously described 6F2 mutant.
Given the related phenotypes of these two mutants, and the well-appreciated
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interactions of SmD3 with RNA, we assayed for the expression of the rpL13a snoRNAs
in 6H2 cells by RNase protection assay. Following palmitate treatment, WT cells show
the expected increase in snoRNA expression by RNase protection (Figure 3.5A). Under
the same conditions, snoRNA induction is blunted in 6H2 cells. Similarly, SmD3
knockdown clones were impaired in rpL13a snoRNA induction relative to control (Figure
3.5B). While snoRNAs are thought to be produced in the nucleus and canonical box
C/D snoRNAs function in that location, our data demonstrates that rpL13a snoRNAs
accumulate in the cytosol during metabolic stress (Chapter 2). Fractionation of WT and
6H2 cells by sequential detergent solubilization revealed that under basal conditions
snoRNAs are detectable in the nucleus and the cytosol but are substantially more
abundant in the nucleus (Figures 3.5C and 3.5D). qRT-PCR analysis of these fractions
reveals reduced rpL13a snoRNAs in the cytosol in 6H2 cells under palmitate-treated
conditions, and reduced levels of these snoRNAs in the nucleus under both basal and
palmitate-treated

conditions

(Figures

3.5E

and

3.5F).

The

observation

that

haploinsufficiency of SmD3 caused impairment of basal expression and lipotoxic
cytosolic accumulation of the intronic rpL13a snoRNAs, a deficit known to cause
resistance to lipotoxicity, is consistent with the ROS resistant phenotype observed in
6H2 cells. Furthermore, the observation that nuclear levels of the rpL13a snoRNAs are
decreased in 6H2 cells under basal as well as lipotoxic conditions implicates a defect in
the nuclear production of the snoRNAs.
To test whether 6H2 cells have a general defect in expression of intronic
snoRNAs, we measured basal nuclear expression of intronic box C/D snoRNAs U50,
U57, U60, and U21 and intronic box H/ACA snoRNAs U17b, U64, and ACA28 (Figure
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3.5G). Expression of each of these snoRNAs was reduced in the nuclei of 6H2 versus
WT

cells.

Furthermore,

we

measured

the

expression

of

intronic

splicing-

dependent/Drosha-independent pre-miRNAs to probe an unrelated class of intronic
ncRNAs (6, 89). Mirtrons miR-1224 and miR-1225 showed reduced expression in 6H2
cells. In contrast, independently transcribed, splicing-independent, non-intronic
snoRNAs U8 and U13 and pre-miR-23a showed no difference in expression between
WT and 6H2. Taken together, these data suggest that WT levels of SmD3 are generally
required for effective expression of splicing-dependent intronic ncRNAs.

SmD3 knockdown perturbs snRNP biogenesis. Disruption of multiple components of
the snRNP assembly pathway has previously been shown to alter snRNP expression
(98, 130). To test whether reduced levels of SmD3 affect snRNA expression, we used a
chimeric locked nucleic acid/DNA (LNA/DNA) oligonucleotide to specifically knockdown
SmD3 in murine fibroblasts. Following knockdown of SmD3 to ~50% of control SmD3
levels, we observed reductions in rpL13a snoRNAs similar to our mutant, (Figures 3.6A
and 3.6B).

In SmD3 knockdown cells, qRT-PCR revealed that U4 and U5 snRNA

expression was decreased, but levels of other snRNAs were indistinguishable from
control (Figure 3.6C). Since unbound snRNAs are unstable compared to snRNAs in
snRNP complexes, quantification of snRNA levels provides insight into snRNP integrity
(91, 131). Consistent with this, U4 and U5 snRNAs were reduced following
immunoprecipitation with the α-Sm protein Y12 antibody, indicating that U4 and U5
snRNPs are also diminished (Figure 3.6D). By contrast, 50% knockdown of SmB,
another Sm protein family member, produced more modest decreases in snoRNA
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production (Figure 3.6F). SmB knockdown cells remained sensitive to palmitate-induced
death (Figure 3.6G) and displayed a different pattern of alteration of snRNA expression,
characterized by decreases in U2 and U4 and increase in U4atac (Figure 3.6H). Our
data suggest that a reduction in SmD3 expression disrupts a specific set of snRNPs.
While there is some overlap with the effects of SmB knockdown on snRNA levels, the
pattern with SmD3 is distinct.

6H2 cells display normal splicing efficiency. Given that SmD3 levels affect snRNP
expression, we hypothesized that differences in intronic ncRNA expression caused by
SmD3 haploinsufficiency in the 6H2 cells could be explained by a defect in splicing. To
assess splicing related to the rpL13a snoRNAs, we measured the expression of
endogenous rpL13a splicing precursors and spliced products. There was no difference
in rpL13a pre-mRNA levels between WT and 6H2 cells under basal or palmitate-treated
conditions, as assessed by amplifying random hexamer-primed cDNA with primer pairs
designed across the junction between exon 3 and intron 3 (Ex3/Int3, Figures 3.7A and
3.7B). Quantification of the endogenous rpL13a mRNA, using oligo-dT-primed cDNA
and primers designed across the splice junction between exons 7 and 8, showed similar
expression between WT and 6H2 cells (Ex7/8, Figures 3.7A and 3.7B). Furthermore,
priming across four splice junctions formed by the removal of snoRNA-encoding introns
(Ex 2/3, 4/5, 5/6, and 6/7) displayed similar expression between WT and 6H2 cells
(Figures 3.7A and 3.7B).
To assess splicing efficiency more broadly, we transfected WT and 6H2 cells
with a previously validated reporter construct for expression of firefly luciferase from two
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exons separated by a β-globin intron (128). Functional splicing results in the formation
of a luciferase mRNA encoding a protein with measurable luminescence and a
processed β-globin intron lariat. In the absence of splicing, a truncated luciferase protein
without enzymatic activity is formed due to multiple in-frame stop codons. Following
transfection of this construct, no difference in luciferase production was detected
between WT and 6H2 under untreated or palmitate treated conditions or in the presence
of clotrimazole, a known splicing inhibitor (128) (Figure 3.7C). To test whether the
presence of an intronic snoRNA affected splicing of flanking exons in 6H2 cells, we
replaced the intron in the split luciferase vector with the murine rpL13a intron 2
containing U32a. Following transfection with this construct, there was no difference in
luciferase levels between WT and 6H2 cells, although expression of the exogenous
murine U32a was reduced in 6H2 cells (Figures 3.7D and 3.7E). Similarly, we detected
no difference in luminescence using a Δsno split luciferase splicing reporter containing
mutated rpL13a intron 2 sequences lacking the entire 83 nucleotide U32a, and premRNA from the reporters with the intact U32a intron and the Δsno intron were
comparable (not shown). Furthermore, we quantified mRNA expression of the host
genes containing the intronic non-coding elements quantified in Figure 3.5G. We
detected no differences in mRNA levels from any of these host genes between WT and
6H2 cells (Figure 3.7F). Together, these data indicate that differences in intronic noncoding RNA levels are not attributable to defective splicing of exons in 6H2 cells.

SmD3 knockdown does not alter alternative splicing. Previously, it was reported
that 85% or more knockdown of the survival of motor neuron (SMN) protein disrupts the
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snRNP assembly pathway and leads to widespread differences in snRNA levels and
alternative splicing in a number of tissues (130). To test whether reduced levels of
SmD3 affected snoRNA processing through broad alterations in alternative splicing,
exon utilization in control (GFP) and SmD3 knockdown cells was analyzed using the
Affymetrix GeneChip mouse exon 1.0 ST microarray. Due to the lack of publically
available exon microarrays containing hamster sequences, we used our LNA/DNA
oligonucleotides to generate murine fibroblasts with haploinsufficiency of SmD3 to
phenocopy the 6H2 cells that have 50% wild type CHO levels for this protein (Figures
3.6A and 3.6B). Following knockdown, RNA was harvested from three independent
samples of GFP and SmD3 knockdown cells. Among the 266,200 probesets supported
by putative full-length mRNA, ∼190,000 probesets with significant signals above
background and representing exons of ~16,000 out of ~30,000 genes in the mouse
genome were included in the analysis. With a false discovery rate set at less than 0.1,
no genes were identified as having potential splicing pattern changes (fold change ≥
1.5). Plotting probeset intensity values from control (GFP LNA) samples against SmD3
knockdown samples revealed a highly linear relationship (R2 = 0.98475), consistent with
little variance between the two groups (Figure 3.8). These data show that a 50%
reduction in SmD3 expression does not have global effects on alternative splicing.

SmD3 controls intron lariat abundance. Box C/D snoRNAs, box H/ACA snoRNAs,
and mirtrons are each defined by unique consensus sequences, protein assembly
factors, and position within the intron (6, 38, 69, 88, 89). Nonetheless, these intronic
non-coding RNAs all require pre-mRNA splicing, intron lariat formation, debranching,
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and exonucleolytic trimming prior to formation of a functional ribonucleoprotein. We
used qRT-PCR to probe snoRNA precursors to determine the level of processing at
which 6H2 cells are defective. Intron lariats from each rpL13a snoRNA-containing intron
were quantified by qPCR primers reading across the branch point with a sense primer
designed to a 3’ region of the intron and an antisense primer to a 5’ region (116). This
approach revealed a 38-63% decrease in lariats from each of the snoRNA-containing
rpL13a introns under untreated and palmitate treated conditions in 6H2 cells (Figure
3.9A). Validity of this approach was confirmed by the observation of a single PCR
product for each intron lariat (Figure 3.9B) and sequence analysis of the PCR products
(Figure 3.9C). Each primer pair read across the branch point and allowed for mapping
branch sites in rpL13a introns, each defined by an adenosine and 6 of 7 nucleotides
correlating with the consensus major spliceosome branch site. Interestingly, we were
unable to detect PCR products for endogenous rpL13a intron lariats lacking snoRNAs, a
finding consistent with recent work from others showing that intronic sequences lacking
snoRNAs are degraded more quickly than introns containing snoRNAs (126). On the
other hand, we were able to quantify both snoRNA-containing and non-snoRNAcontaining introns when they were overexpressed in cells transfected with the split
luciferase vector construct containing the U32a intron and the snoRNA-deleted U32a
sequence, respectively. In WT cells the presence of the intronic snoRNA was
associated with increased lariat abundance, whereas this apparent increase was not
observed in 6H2 cells (Figure 3.9D). These findings suggest that SmD3 contributes to
expression of intronic snoRNAs by enhancing intron lariat formation or stability.
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CONCLUSIONS
Through the use of a genetic screen in CHO cells, our laboratory has identified
loci involved in lipid-induced cell death, a process in which oxidative stress is a central
feature. Lipotoxic and oxidative stress critically involve cytosolic expression of intronic
snoRNAs from the rpL13a genomic locus (72). We provide additional insight into the
underlying mechanisms of metabolic stress responses through the characterization of a
mutant cell line with disruption of one allele of the gene encoding SmD3. Our data show
that reduced cellular levels of SmD3 decrease the propagation of oxidative stress and
protect cells from palmitate-induced death. Although mutant 6H2 cells are distinct from
previously described palmitate-resistant mutants from our screen, mutation at the SmD3
locus confers a related molecular phenotype in that 6H2 cells fail to induce rpL13a
snoRNAs under lipotoxic stress. We show that SmD3, beyond its known role in splicing,
regulates expression of the intronic snoRNAs. Compared to WT levels of SmD3,
reduced levels of SmD3 lead to decreased intron lariat abundance and decreases in U4
and U5 snRNPs necessary for intron lariat formation. These perturbations decrease the
basal levels of the rpL13a intronic snoRNAs and subsequently blunt their induction
during lipotoxicity.
SmD3 together with six other Sm proteins form a heptameric ring around the
uridine-rich Sm-binding site found in snRNAs. These snRNPs form the major building
blocks of the spliceosome. Sequential assembly of the hetero-oligomers of SmD1-D2,
SmE-F-G, and SmB/B’-D3 is a highly regulated process (27, 84). Although these
proteins

are

critical

for

proper

snRNP

assembly,

our

data

indicate

that

haploinsufficiency of SmD3 is sufficient to maintain splicing of a specific endogenous
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pre-mRNA and an exogenously provided splicing reporter under normal growth
conditions. Consistent with an ability to support overall wild type capacity for mRNA
splicing, the growth of mutant 6H2 cells is indistinguishable from parental wild type cells.
These findings suggest that excision of introns during the catalytic stage of splicing
goes to completion and haploinsufficient levels of SmD3 in these cells is not limiting for
production of mRNAs. Furthermore, ~50% knockdown of SmD3 does not cause global
changes in exon utilization. These findings indicate that the phenotype of SmD3
haploinsufficiency does not relate to global defects in formation of mRNAs.
To our knowledge, this is the first report of the loss-of-function phenotype for
SmD3. The finding of a second mutation that reduces rpL13a snoRNA expression and
leads to resistance to lipotoxicity further highlights the important role of these ncRNAs in
metabolic stress responses. More importantly, our study provides novel insights into the
broader molecular cell biology of intronic non-coding RNA elements. Future studies of
the precise molecular interactions of SmD3 within individual snRNPs are likely to
elucidate mechanisms through which this protein regulates non-coding RNA biogenesis.
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Figure 3.1 6H2 cells are resistant to palmitate-induced cell death. (A) WT and palmresistant 6H2 mutant cells were incubated with 500 µM palm for 48 h; or 10 µM
camptothecin (camp), 80 nM staurosporine (staur), or 2 µM actinomycin D (actD) for 24
h. Cell death was quantified by propidium iodide (PI) staining and flow cytometry. Data
are expressed as mean fluorescence ± standard error (SE) for 3 independent
experiments with 104 cells/sample. *, p<0.005 for 6H2 versus WT.
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Figure 3.2

Figure 3.2 6H2 cells are haploinsufficient for SmD3. (A) Autoradiogram shows
Southern blot analysis of WT (lanes 1-3) and 6H2 (lanes 4-6) genomic DNA digested
with restriction enzymes Bgl II, NcoI, or XbaI. Blot was probed with a

32

P-labeled

fragment corresponding to the ROSAβgeo sequence. (B) PCR was performed on cDNA
from WT (lanes 1 and 2) and 6H2 (lanes 3 and 4) cells with reactions containing no
cDNA as controls (lanes 5 and 6). Forward (F) and reverse (R) primers for snrpD3 were
designed to detect endogenous snrpD3 (lanes 1, 3, and 5). Forward snrpD3 primer and
reverse primer for the proviral sequence were used to detect fusion transcript (lanes 2,
4, and 6). (C) RNA was isolated from WT and 6H2 cells and reverse transcribed using
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either random hexamers (ran hex) to prime total RNA or oligo dT to prime mRNA.
snrpD3 expression was determined by quantitative real-time PCR (qPCR) and
normalized to β-actin expression. (D) Protein expression in WT and 6H2 cells was
determined by western blotting and quantified by densitometry. Bands at 15 kDa and 18
kDa likely reflect known post-translational modification of SmD3. Representative blot
shown for SmD3 and β-actin control. On bar graphs, data are expressed as mean ± SE
for three independent experiments. *, p < 0.05 for 6H2 versus WT.
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Figure 3.3
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Figure 3.3 Targeted knockdown of SmD3 confers palmitate-resistance. Stable
clonal cell lines were generated following transfection with a scrambled (contr) or
snrpD3-targeting shRNA (sh1 and sh2). (A) SmD3 and β-actin protein expression was
determined by western blot. Blot shows three independent protein samples from each
respective cell line. (B) SmD3 expression relative to β-actin was quantified by
densitometry of blots as shown in A. Graph shows mean ± SE for three independent
samples. *, p < 0.05 for knockdown versus scrambled. (C) Scrambled and knockdown
cells were treated with palm for 48 h and cell death was assessed by PI staining and
flow cytometry. All data are expressed as mean fluorescence ± SE for three
independent experiments with 104 cells/sample. *, p<0.005 for knockdown versus
scrambled.
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Figure 3.4

Figure 3.4 SmD3 disruption protects cells from palmitate-induced and generalized
oxidative stress induction. (A) WT and 6H2 cells were incubated with

14

C-palmitate

under lipotoxic conditions (500 µM palm). Mean initial rates of palmitate uptake are
expressed per µg protein (± SE) for 3 independent experiments. (B,C,D) WT and 6H2
cells were incubated with palmitate (B, 5 hr and 16 h), scrambled (contr) and
knockdown (sh1 and sh2) cells were treated with palmitate (C, 16 h), or WT and 6H2
cells were untreated (UT) or treated with menadione (mena) or H2O2 (D, 2h). ROS
induction was assessed by CM-H2DCFDA (DCF) labeling and flow cytometry. Graphs
show mean fluorescence ± SE for 3 independent experiments with 104 cells/sample. *,
46

p<0.05 for 6H2 versus WT, or for knockdown versus scrambled.
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Figure 3.5
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Figure 3.5 Intronic non-coding RNA expression is disrupted in 6H2 cells. (A,B) WT
and 6H2 cells (A) and scrambled control and knockdown cells (B) were untreated or
supplemented with palm for 48 h. Small RNA was harvested and used in RNase
protection assay with
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P-labeled rpL13a snoRNA probes or miR-16 probe as control.

	
  

Protected probe was analyzed by autoradiography. (C,D,E,F) WT and 6H2 cells were
untreated or treated with palm for 9 h. Cells were separated into cytosolic (CYT) and
nuclear (NUC) fractions by sequential detergent solubilization. (C) Fractions were
analyzed by western blotting or PCR visualization for cytosolic markers, hsp90 and
tRNAGlu, and for nuclear markers, fibrillarin and U6 RNA. (D) Molar quantities of
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rpL13a snoRNAs from cytosolic and nuclear fractions were quantified relative to a
standard curve. Plot represents relative molar ratio. (E,F) Total RNA was prepared from
the cytosolic (E) and nuclear (F) fractions and analyzed for rpL13a snoRNA abundance
relative to β-actin by qRT-PCR. (G) Total RNA was prepared from nuclear fractions of
WT and 6H2 cells and analyzed for intronic and non-intronic box C/D snoRNAs; intronic
box H/ACA snoRNAs; and splicing-dependent/Drosha-independent intronic and nonintronic miRNAs. All data are expressed as mean ± SE for three independent
experiments. *, p < 0.05 for 6H2 versus WT.
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Figure 3.6
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Figure 3.6 SmD3 knockdown disrupts U4 and U5 snRNPs. (A,B,C,D) NIH 3T3 cells
were transfected with LNA/DNA oligonucleotides specifically targeting GFP or SmD3.
(A) Protein expression in GFP and SmD3 transfected cells was determined by western
blotting and quantified by densitometry. Representative blot shown for SmD3 and βactin control. (B) Nuclear RNA was isolated and analyzed for SmD3 mRNA and rpL13a
snoRNA expression by qRT-PCR relative to 36B4. (C) Total RNA was isolated and
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analyzed for snRNA expression relative to 36B4 by qRT-PCR. (D) Cell lysates were
immunoprecipitated using α-Sm Y12 antibody or IgG control. RNA was isolated
following immunoprecipitation and analyzed by qRT-PCR for α-Sm immunoprecipitated
snRNA relative to control (IgG) precipitated. (E,F,G,H) NIH 3T3 cells were transfected
with control (contr) siRNA or siRNA targeting SmB. (E) Protein expression in control and
SmB siRNA cells was determined by western blotting and quantified by densitometry.
Representative blot shown for SmB and β-actin control. (F) Nuclear RNA was isolated
and analyzed for SmB and rpL13a snoRNA expression by qRT-PCR relative to 36B4.
(G) Control and SmB siRNA cells were incubated with 500 µM palm for 24 h or 48 h.
Cell death was quantified by PI staining and flow cytometry. (H) Total RNA was isolated
and analyzed for snRNA expression by qRT-PCR relative to 36B4. Data are expressed
as mean ± SE for three independent experiments. *, p < 0.05 SmD3 versus GFP or
SmB versus control; ns, not significant.
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Figure 3.7
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Figure 3.7 Host gene expression is normal in 6H2 cells. (A) rpL13a locus is shown
with non-coding region in black lines, exons in black boxes and snoRNAs in gray ovals.
Location of primers for qPCR analysis of pre-mRNA and mRNA are noted. (B) WT and
6H2 cells were untreated (UT) or treated with palm for 9 h. For analysis of rpL13a premRNA expression, total RNA was reverse transcribed using random hexamers, and
amplified using primers that span the junction between exon 3 and intron 3. For analysis
of rpL13a mRNA expression, total RNA was transcribed using oligo-dT and amplified
using primers that span exon-exon junctions. Primer pairs are as indicated in (A). (C)
WT and 6H2 cells were transfected with a split luciferase reporter containing a β-globin
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intron. 24 h post-transfection, cells were untreated or treated with palm or clortrimazole
(clor) for 4 h. Luminescence was measured and normalized to luciferase pre-mRNA
expression by qPCR. (D,E) WT and 6H2 cells were transfected with a split luciferase
construct containing the intact U32a intron (sno) or the U32a intron lacking the 83
nucleotide U32a snoRNA (Δsno). Total RNA was analyzed for luciferase pre-mRNA and
U32a snoRNA expression. Luminescence (D) and U32a snoRNA (E) were normalized
to luciferase pre-mRNA expression. Note that sequences differences between the
murine intronic sequences in the reporter construct and endogenous hamster
sequences enable discrimination between exogenous murine and endogenous hamster
snoRNAs using species-specific PCR primers. (F) Total RNA was prepared from WT
and 6H2 cells and analyzed for host genes of endogenous intron-encoded snoRNAs
and mirtrons by qRT-PCR relative to β-actin mRNA. All data are expressed as mean ±
SE for three independent experiments. *, p < 0.05; ns, not significant.
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Figure 3.8
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Figure 3.8 Alternative splicing is normal in 6H2 cells. Exon array analysis was used
to predict differences in alternative splicing. Relative probeset intensity values from
exon array were plotted for SmD3 LNA versus GFP LNA transfected cells using data
from three independent samples/arrays for each condition.
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Figure 3.9
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Figure 3.9 SnoRNA-containing intron lariats are decreased in 6H2 cells. (A) WT
and 6H2 CHO cells were untreated or treated with palm for 9 h. Nuclear RNA was
isolated and reverse transcribed using random hexamers. rpL13a intron lariat
abundance was determined by qRT-PCR using primers reading across branch points
(red arrows in diagram). Quantification of lariat PCR product is normalized to β-actin
mRNA. (B,C) PCR products generated by intron lariat primers in CHO WT cells were
visualized on 2% agarose gel (B) or cloned and sequenced (C). (B) Lanes with cDNA
(+) contain RT product as template. Lanes without cDNA (-) were negative control PCR
reactions with no RT product provided as template. (C) Sequencing revealed the branch
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site adenosine (red) for each intron. Branch site nucleotides showing conservation
(uppercase) are indicated. (D) WT and 6H2 cells were transfected with a split luciferase
construct containing the intact murine U32a intron (sno) or the U32a intron lacking the
83 nucleotide U32a snoRNA (Δsno). Intron lariat abundance was determined by qRTPCR using primers specific for the murine lariat sequences and normalized to luciferase
pre-mRNA expression. All data are expressed as mean ± SE for three independent
experiments. *, p < 0.05; ns, not significant.
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Figure 3.10
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Figure 3.10 Role for SmD3 in snoRNA production. A model for SmD3 role in
snoRNA production is shown. Open boxes denote exons; black lines denote intronic
sequences; and snoRNA sequences are shown in yellow and blue. Colored balls
represent snRNPs. In the presence of wild type levels of SmD3, the complement of
snRNAs is sufficient to support splicing of pre-mRNAs into mature mRNAs and intron
lariats that are sufficiently long-lived to produce snoRNAs. While haploinsufficiency of
SmD3 is able to support wild type levels of mRNA production from splicing, associated
decreases in the abundance of the of U4 and U5 snRNPs results in decreased intron
lariat abundance and decreased levels of intronic snoRNAs (yellow, blue).	
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CHAPTER 4
Superoxide triggers cytosolic snoRNA accumulation

INTRODUCTION
Under physiological conditions, ROS serve a number of critical functions.
Superoxide (O2-) and hydrogen peroxide (H2O2) are known to regulate gene expression
by signaling through phosphatases, JAK/STATs, MAP kinases, and transcription factors
including NF-κB (34). ROS levels are kept in check by antioxidant enzymes and
scavengers including dismutases, peroxiredoxins, glutathione peroxidases, and
catalase.
Under pathophysiological conditions, when ROS generation exceeds cellular
antioxidant defenses, oxidative stress results. The rpL13a snoRNAs are critical for ROS
propagation during lipotoxic stress (72). NADPH oxidase activation is also important for
FFA-induced oxidative stress, since inhibition of NADPH oxidase blocks lipotoxic cell
death (11). Lipotoxic conditions can activate NADPH oxidase through ceramide
synthesis or, in the absense of de novo ceramide synthesis, through protein kinase C
(PKC) dependent pathways (45, 61).
Nox enzymes generate ROS by transferring electrons from NADPH to molecular
oxygen. O2- is the primary product of Nox enzymes, and Nox4 is also able to produce
H2O2. In many cell types including cardiomyocytes and cardiac fibroblasts, Nox2 and
Nox4 are the predominant NADPH oxidases (67). Nox2 is normally quiescent, and its
activation requires stimulus-induced membrane translocation of cytosolic regulatory
subunits, including p47phox, p67phox, p40phox, and Rac1, a small GTPase. This
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translocation is triggered by phosphorylation of p47phox by PKC (2). Nox4 is
constitutively active when assembled as a heterodimer with p22phox. Nox4 ROS
generation does not require association of cytosolic factors but is regulated at the gene
expression level.
Given that NADPH oxidase activation is a critical contributor to ROS generation
during lipotoxicity, we hypothesized that specific ROS (e.g. O2-) may be linked to ROS
propagation driven by the rpL13a snoRNAs. Here, we demonstrate a link between O2induction and cytosolic rpL13a snoRNA accumulation. Our results extend the known
relationship between ROS and rpL13a snoRNAs, suggesting a role for these snoRNAs
in additional oxidative stress-related diseases.

RESULTS
Palmitate-induced

superoxide

precedes

cytosolic

snoRNA

accumulation.

Following palmitate treatment, rpL13a snoRNAs accumulate in the cytosol in a timedependent fashion in H9c2 cells (Figure 4.1A). By 6 hr following palmitate treatment,
U32a, U33, and U34 are elevated ~2-fold in the cytosol, and U35a is elevated 1.5-fold.
Since rpL13a snoRNAs are critical for ROS propagation during lipotoxicity, we
hypothesized that rpL13a snoRNAs participate in a feed-forward ROS cascade initiated
by ROS production following palmitate treatment. O2- is produced during lipotoxicity
through NADPH oxidase (31). To test how quickly O2- is generated following palmitate
treatment, we quantified O2- production in cells treated with palmitate in the presence of
the O2- detector MCLA. Palmitate treatment rapidly raised O2- levels, and levels
remained high compared to untreated cells over the course of 1 hr (Figure 4.1B) These
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data indicate O2- induction is an early response to lipotoxicity and precedes cytosolic
snoRNA accumulation.

Direct superoxide induction causes rapid cytosolic snoRNA accumulation. To test
whether O2- generation can induce cytosolic snoRNA accumulation independent of
metabolic stress, we treated H9c2 cells with chemical inducers of O2-. Since O2- can be
rapidly dismutated into H2O2, we initially examined the relative production of H2O2
following treatment with menadione and doxorubicin. We loaded cells with DCF to track
H2O2 generation and observed a dose dependent increase in DCF signal following
menadione treatment (Figure 4.2B). In comparison, doxorubicin generated less than
half the H2O2 of menadione even at high concentrations, suggesting doxorubicin is not a
potent inducer of H2O2.
We confirmed that doxorubicin generates O2- in H9c2 cells by treating cells with
doxorubicin for 1 hr followed by O2- detection by MCLA. We detected a dose dependent
increase in O2- production (Figure 4.3A). Since doxorubicin generates O2- while only
producing modest levels of H2O2, we wanted to test whether doxorubicin could induce
cytosolic snoRNA accumulation. Following treatment with doxorubicin, we observed
rapid accumulation of rpL13a snoRNAs in the cytosol (Figure 4.3B). U32a, U33, and
U34 were up-regulated by at least 2.5 fold as early as 20 min following palmitate
treatment. Additionally, the magnitude of cytosolic snoRNA expression was higher than
observed following palmitate treatment in H9c2 cells or other cell types (72, 94). These
data suggest that direct O2- induction can rapidly and robustly induce cytosolic snoRNA
accumulation.
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Superoxide levels correlate with cytosolic snoRNA accumulation. Conversion of
O2- to H2O2 is predominately regulated by superoxide dismutases (SOD). Isoforms of
these antioxidant enzymes are located throughout the cell and extracellular space.
SOD1 is located in the mitochondrial intermembrane space and cytosol, SOD2 is
located in the mitochondrial matrix, and SOD3 is tethered to the extracellular matrix
(95). We hypothesized that chemical manipulation of these enzymes would alter O2levels and subsequently alter levels of rpL13a snoRNAs in the cytosol. To increase
levels of O2-, we co-treated cells with doxorubicin and diethyldithiocarbamate (DETC),
an SOD inhibitor (Figure 4.4A) We also co-treated cells with doxorubicin and MnTBAP,
an SOD mimic, to increase O2- scavenging and subsequently decrease O2- levels
(Figure 4.4A). RpL13a cytosolic snoRNA expression correlated with these changes in
O2- levels (Figure 4.4B). Relative to doxorubicin treatment alone, U32a, U33, and U34
all showed increased cytosolic accumulation following co-treatment with doxorubicin
and DETC and decreased cytosolic accumulation following co-treatment with
doxorubicin and MnTBAP. U35a was unaltered by doxorubicin treatment but was upregulated following co-treatment with doxorubicin and DETC. Although doxorubicin cotreatment with MnTBAP lowered cytosolic snoRNA levels relative to doxorubicin
treatment alone, snoRNA levels remained higher in the presence of doxorubicin and
MnTBAP than in H2O-treated control cells, despite lower O2- levels in the MnTBAP
treated cells. These data suggest O2- contributes to cytosolic snoRNA localization, but
other factors likely contribute and may be important for localization of U35a in particular.
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CONCLUSIONS
The rpL13a snoRNAs are critical for ROS propagation in response to metabolic
stress. Cytosolic localization of these snoRNAs is thought to be an important feature of
the function of these non-coding RNAs during lipid-induced oxidative stress. Here, we
demonstrate a link between ROS induction and cytosolic snoRNA accumulation.
Specifically, O2- induction precedes cytosolic snoRNA accumulation under lipotoxic
conditions. Doxorubicin induced O2- also causes rpL13a snoRNAs to localize to the
cytosol independent of metabolic stress. Manipulation of O2- demonstrates that O2levels directly correlate with cytosolic snoRNA expression. Our data are consistent with
a model in which palmitate and direct O2- inducers stimulate higher levels of O2- in the
cells. This O2- provides a signal to nuclear snoRNAs, through a pathway yet to be
elucidated, causing translocation of snoRNAs to the cytosol (Figure 4.5)
Additional experimentation will be required to determine the source of O2- under
lipotoxic conditions. We hypothesize that NADPH oxidase is that source of O2-.
Inhibition of NADPH oxidase or Nox enzyme knockdown will enable determination of the
role of NADPH oxidase in cytosolic snoRNA accumulation. Apocynin is an NADPH
oxidase inhibitor that prevents the assembly of NADPH oxidase subunits. Diphenylene
iodium (DPI) is a non-specific inhibitor of flavoenzymes including NADPH oxidase,
quinone oxidoreductase, cytochrome P450 reductase, and nitric oxide synthase (59).
Inhibition with either of apocynin or DPI could be used to test whether NADPH oxidase
is generally involved in cytosolic snoRNA localization. Additionally, directed knockdown
of Nox2, p22phox, or p47phox would help elucidate whether specific NADPH oxidase
components are related to snoRNA localization. Nox2 knockdown would directly target
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a predominant source of O2-. Knockdown of p22phox would test whether any of the Nox
enzymes 1-4 are involved, and knockdown of p47phox would test whether a key cytosolic
component required for Nox1-3 activity is related to snoRNA expression.
Additionally, we propose that palmitate-induced oxidative damage is amplified by
cytosolic snoRNA accumulation (72). Following O2- reduction by MnTBAP or NADPH
oxidase inhibition/knockdown, we hypothesize that oxidative damage will be reduced
during lipotoxicity. To test this hypothesis, protein carbonylation and palmitate-induction
of cell death will be quantified in future studies in cells expressing various levels of O2-.
Finally, it will be of great interest to determine the specificity of relationship
between specific ROS species and the broader genomic program of snoRNAs. We
hypothesize that specific ROS regulate different snoRNAs. Preliminary data from our
lab suggests a number of additional snoRNAs are found in the cytosol during lipotoxicity
(not shown). Even though U32a, U33, U34, and U35a are produced from the same premRNA, our data suggest that the kinetics or the specificity of ROS-stimulated
relocalization to the cytosol differs among these snoRNAs. Since oxidative stress is the
result of the propagation of various ROS induced at different times, we propose that
individual snoRNAs respond specifically to different ROS. To test this hypothesis, we
will use a custom Agilent microarray developed in our lab that enables quantitative
detection of approximately 300 known and predicted snoRNAs to determine the
program of snoRNAs that accumulate in the cytosol following specific induction of O2vs. H2O2 vs. other ROS species. Changes identified in snoRNA expression will be
confirmed by qPCR and in situ hybridization.
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Together, our data suggest an intricate connection between ROS and snoRNA
localization. Future studies will be needed to elucidate the mechanisms through which
O2- and other ROS signal to snoRNAs and will broaden our understanding of the
contributions of these non-coding RNAs to metabolic stress.
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Figure 4.1 Palmitate induces superoxide. (A) H9c2 cardiomyoblast cells were treated
with BSA or treated with 500 µM palmitate for 3, 6, 12, or 24 h. Cytosolic fractions were
isolated from cells by sequential detergent solubilization. Total RNA was prepared from
the cytosolic fraction and analyzed for rpL13a snoRNA and mRNA abundance relative
to 36B4 by qRT-PCR. Graph shows mean ± SE (n = 3) from a representative
experiment. (B) H9c2 cells were untreated (UT) or treated with palmitate (palm) in 2methyl-6-(4-methoxyphenyl)-3,7-dihydroimidazol[1,2-A]pyrazin-3-one,
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hydrochloride

(MCLA) buffer for 60 min. Luminescence was measured every 30 sec and normalized to
a superoxide dismutase-treated control.
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Figure 4.2
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Figure 4.2 Doxorubicin is not a potent H2O2 inducer. (A) Superoxide (O2-) is rapidly
dismutated by the antioxidant enzyme superoxide dismutase (SOD), leading to the
formation of hydrogen peroxide (H2O2) and molecular oxygen. (B,C) H9c2 cells preloaded with CM-H2DCFDA (DCF) dye were untreated (UT) or treated with menadione
(mena) or doxorubicin (dox) for 60 min. H2O2 induction was assessed by DCF
fluorescence

every

2

min

using
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Figure 4.3 Doxorubicin induces rapid cytosolic rpL13a snoRNA accumulation. (A)
H9c2 cells were untreated (UT) or treated with doxorubicin (dox) for 60 min. Superoxide
induction was assessed by MCLA. Luminescence was measured every 30 sec and
integrated luminescence over 3 min is reported normalized to an SOD treated control.
(B) H9c2 cells were untreated (UT) or treated with 20 µM doxorubicin for 20 min, 60
min, 12 h, or 24 h. Cytosolic fractions were isolated from cells by sequential detergent
solubilization. Total RNA was prepared from the cytosolic fraction and analyzed for
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rpL13a snoRNA and mRNA abundance relative to 36B4 by qRT-PCR. Graph shows
mean ± SE (n = 3) from a representative experiment.
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Figure 4.4
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Figure 4.4 Manipulation of superoxide alters cytosolic rpL13a snoRNA
accumulation. (A,B) H9c2 cells were untreated (UT) or treated with 5 µM doxorubicin
(dox) for 60 min. Cells were co-treated with H2O, 400 µM diethyldithiocarbamic acid
(DETC), or 400 µM manganese(III) tetrakis(4-benzoic acid)porphyrin chloride
(MnTBAP). (A) Superoxide induction was assessed by MCLA. Luminescence was
measured every 30 sec and integrated luminescence over 3 min is reported normalized
to an SOD treated control. (B) Cytosolic fractions were isolated from cells by sequential
detergent solubilization. Total RNA was prepared from the cytosolic fraction and
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analyzed for rpL13a snoRNA and mRNA abundance relative to 36B4 by qRT-PCR.
Graph shows mean ± SE from a representative experiment.	
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Figure 4.5
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Figure 4.5 Superoxide is linked to cytoplasmic snoRNA accumulation. A model for
the role of superoxide in cytoplasmic snoRNA accumulation is shown. Treatment with
palmitate or doxorubicin causes increased levels of superoxide radicals. Through an
unknown mechanism, superoxide signals nuclear snoRNAs to accumulate in the
cytoplasm. SnoRNAs are shown in green, purple, yellow, and blue.
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CHAPTER 5
Discussion
Genetic screens provide powerful approaches to dissect cell biological
phenomena. Inherent in this approach is the advantage that genes are identified on the
basis of their functional contributions to the pathway of study. Since multiple mutations
may affect different components in the pathway, genetic approaches also have the
ability to elucidate interacting elements. Our screen for mutations that render cells
resistant to lipotoxicity identified rpL13a snoRNAs as critical mediators of metabolic
stress. Identification of a second, independent mutation that disrupts the expression of
these snoRNAs highlights the importance of ncRNAs in lipotoxicity. With this second
mutant, we identified SmD3 as an upstream regulatory element necessary for the
expression of rpL13a snoRNAs. Thus, in an unbiased genetic screen, we identified
unexpected elements of the lipotoxic response.
Phenotypic characterization of the 6F2 and 6H2 mutants revealed that rpL13a
snoRNAs are also involved in the general response to oxidative stress. Previous
biochemical studies in diverse cell types have correlated lipotoxic stress with the
generation of ROS (7, 45). The rpL13a snoRNAs provide evidence of a functional link
between the progress of lipotoxic cell death and the deleterious cellular response to
oxidative stress. While transcriptional, posttranslational, and signaling mechanisms are
known to contribute to the cellular response to oxidative stress (33, 41), our studies are
the first to implicate snoRNAs in the response to environmental perturbations.
A key observation that facilitated our understanding of the contributions of the
rpL13a locus to lipotoxicity was the extent of sequence conservation of this gene
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beyond the protein-coding exons. Four box C/D snoRNAs, U32a, U33, U34, and U35a
located in rpL13a introns 2, 4, 5, and 6, respectively, are highly conserved across
mammalian species both in terms of their primary sequence and their position within the
locus. While box C/D snoRNAs function as guides for 2’-O-methylation in yeast (Lowe
and Eddy, 1999), the sequences of the U32a, U33, U34, and U35a snoRNAs and their
genomic organization diverge substantially from yeast to mammals. In mammals, a role
in the modification of ribosomal RNAs has not been demonstrated for these snoRNAs.
We show here in a stable mutant cell line that decreased basal expression of U32a,
U33, and U35a snoRNAs and loss of palmitate induction of these snoRNAs is not
associated with changes in 2’-O-methylation of predicted rRNA targets, yet is
associated with resistance to lipotoxicity. While it is possible that these snoRNAs
contain more than one functional guide sequence to target multiple substrates including
rRNAs (13, 110), their accumulation in the cytosol during lipotoxicity suggests a nonnucleolar function for these snoRNAs.
Movement of snoRNAs to the cytosol is not without precedent, since the
independently transcribed box C/D snoRNA, U8, has been shown to be exported from
the nucleus (121). The present study provides the first direct evidence for intronic
snoRNAs in the cytosol. Our data are most consistent with a model in which the rpL13a
snoRNAs function in lipotoxicity and oxidative stress response pathways as noncanonical box C/D snoRNAs. Our results demonstrate that U32a, U33, and U35a
function coordinately in propagation of oxidative stress in vivo. Thus, our study provides
evidence for snoRNA regulation of metabolic stress response pathways.
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Cytosolic functions of snoRNAs
The cytosolic function of snoRNAs has yet to be elucidated. We hypothesize that
snoRNAs serve to guide the modification of cytosolic target RNAs during metabolic
stress. Cytosolic ncRNAs, particularly tRNAs, are known targets for modification. tRNAs
are subject to over 75 different modifications throughout their sequence. Modifications
to the anticodon loop can influence the recognition of codons and maintenance of the
translational reading frame (32). Although pre-mRNA are known to undergo 5’ m7G
capping, 3’ polyadenylation, and RNA splicing, modification of individual nucleotides
within cytosolic mRNAs is not well described. The abundance of modifications in tRNA,
rRNA, and snRNA raises the possibility that mRNAs might also be modified.
SnoRNAs could function in the regulation of mRNA translation, possibly through
targeted modification or sequestration of specific mRNAs. Recently, it was
demonstrated that targeted pseudouridylation of termination codons suppresses
translation termination in vitro (48). Given the manifold of changes in gene expression
during the lipotoxic and oxidative stress responses (10), the coordinate function of the
rpL13a snoRNAs (72), lack of a well-defined long stretch of perfect antisense homology
to targets in snoRNAs (53), and the possibility that snoRNA-directed modifications of
RNA targets may not be reflected by changes in abundance of those RNAs,
identification of specific targets for each of these snoRNAs will be a complex task and
the subject of future investigations. To identify individual targets of rpL13a snoRNAs,
transfection of cells with synthetic biotin-labeled snoRNA molecules could facilitate pulldown of RNA species that interact specifically with rpL13a snoRNAs. While initial
approaches may utilize biochemical isolation of specific snoRNA-targetRNA complexes,
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it will also be of great interest to examine 2’-O-methylation and pseudouridylation on a
genome-wide level.
Identification of precise snoRNA localization within the cytosol will also be useful
for understanding the function of snoRNAs during metabolic stress. Moreover, our initial
studies suggest that snoRNAs are subject to cellular export. Treatment of cultured cells
with palmitate leads to detectable snoRNA expression in culture media. Additionally,
snoRNAs are stably expressed in human and mouse serum, and treatment of 12-weekold mice with LPS results in increased serum snoRNA expression (not shown). Thus,
snoRNAs may be readily exported from cells. A number of recent studies have shown
that miRNAs are released from cells after cell death, in apoptotic bodies, through
microvesicles including exosomes, and as part of protein complexes giving precedence
for extracellular ncRNAs (106, 113, 114). If future studies confirm a role for snoRNA
secretion in response to lipotoxicity and oxidative stress, circulating snoRNAs could
ultimately serve as a biomarkers for diseases characterized by oxidative stress.

Regulation of snoRNA processing
Identification of SmD3 through our genetic screen unmasks a previously
unsuspected role for this protein in production of intronic snoRNAs. The precise
mechanisms through which SmD3 regulates intronic snoRNA expression remain to be
determined. One possibility is that SmD3 has a direct role in snoRNA biogenesis
unrelated to its function in snRNPs. Unlike SmD3 haploinsufficient cells, SmB
knockdown cells remain sensitive to palmitate-induced death suggesting that SmD3 has
a function distinct from other Sm protein family members. Additionally, SmD3 has been
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observed to function independently from the Sm core in the cytoplasm (30). SmD3 has
also been previously shown to bind small Cajal body RNAs (scaRNAs), a class of
snoRNAs specifically localizing to Cajal bodies, and human telomerase (hTR) via a CAB
box site (28). However, H/ACA snoRNAs U17b and U64, which are affected by
haploinsufficiency of SmD3, both lack CAB box sequences. Additional studies will be
required to decipher whether SmD3 can function independently from the Sm core during
snoRNA biogenesis.
Our data are most consistent with a model in which SmD3 does not directly
interact with the maturing snoRNA during processing, but rather controls processing
indirectly through a role in snRNP assembly and/or stabilization (Figure 3.10).
Knockdown of SmD3 results in decreased expression of U4 and U5 snRNPs that are
required for precatalytic spliceosome formation and initiation of an active spliceosome
capable of intron lariat formation (68). Furthermore, reduced expression of snoRNA
lariat precursors, resulting from decreased lariat production or stability, leads to
decreased abundance of the mature intronic snoRNAs and failure to support their
induction during lipotoxicity in 6H2 cells. These differences in intron lariat abundance
and snRNP expression suggest that the phenotype observed in 6H2 cells is related to
spliceosomal machinery, even though haploinsufficiency of SmD3 is sufficient to
maintain production of mRNAs.
We also observed that wild type levels of SmD3 are critical for the ability to
express a number of intronic non-coding RNA elements including other box C/D
snoRNAs, H/ACA snoRNAs, and mirtrons. These ncRNAs do not share significant
sequence similarities and each assembles with a unique set of proteins during
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processing, making it unlikely that SmD3 directly recognizes and associates with the
nascent RNP. It has been shown that the C-terminal tail of SmD3 interacts with the
central Tudor domain of splicing factor SPF30 (62), indicating that SmD3 may be
important for the assembly of splicing factors specific to individual snRNPs. Individual
Sm proteins may be critical for the assembly of specific factors within different snRNPs
consistent with the different snRNA expression profiles observed following SmD3
knockdown versus SmB knockdown. In follow up, it will be of interest to determine
whether Sm protein-splicing factor interactions are critical for SmD3’s role in snRNP
assembly and/or stabilization and to better define the distinct but overlapping roles of
SmD3 and SmB in assembly and stabilization of snRNPs.

Regulation of snoRNA localization
SnoRNAs are processed in the nucleus and canonically reside within the
nucleolus. Our studies indicate that nuclear snoRNA levels are multiple orders of
magnitude higher in the nucleus than the cytoplasm even during metabolic stress.
Unlike snRNAs, snoRNAs are not thought to undergo a cytosolic phase during
maturation (69), suggesting that accumulation of snoRNAs in the cytosol requires an
active mechanism. We demonstrate that O2- induction precedes cytosolic snoRNA
accumulation consistent with the hypothesis that O2- functions as an upstream trigger of
snoRNA translocation from the nucleus to the cytosol. O2- participates in multiple
signaling pathways (34). ROS driven signal transduction includes induction of gene
expression, protein phosphorylation, and alteration of redox status (73). Examination of
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O2- signaling pathways, particularly in the nucleus, will be of great interest in future
studies of ROS regulated snoRNA localization.
O2- diffuses only short distances before reacting with a target, so it is likely that
the source of O2- related to snoRNAs is generated in close proximity to its intended
target. Although NADPH oxidases are implicated to be involved in lipotoxicity, the
source of O2- leading to cytosolic snoRNAs remains to be elucidated. Nox enzymes
each have distinct subcellular localizations. Nox2 is found predominantly on the plasma
membrane, whereas Nox4 is located in intracellular membranes. O2- can also be
generated from several additional sources, including xanthine oxidases, peroxidases,
lipoxygenases, cyclooxygenases, and mitochondrial respiratory chain complexes (129).
Determination of the source of O2- will help elucidate how O2- is linked to cytosolic
snoRNA accumulation.
	
  
Summary
Together, our data demonstrate that snoRNAs are highly regulated in response
to metabolic stress and contribute significantly to the pathogenesis of oxidative stress.
To carry out this role, snoRNAs must be efficiently processed and properly localized.
Elucidation of the regulatory steps in snoRNA production and localization and
identification of targets for non-canonical snoRNAs will advance our understanding of
the pathogenesis of common human diseases. Moreover, regulation of snoRNAs
provides potential therapeutic targets for oxidative stress-related diseases including
type 2 diabetes.
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CHAPTER 6
Materials and Methods

Materials. Palmitate was from Nu-Chek Prep.

14

C-palmitate and α-32P-UTP were from

PerkinElmer Life Sciences. Camptothecin, actinomycin D, hygromycin, and MnTBAP
were from Calbiochem. Staurosporine, H2O2, menadione, phloretin, clotrimazole,
doxorubicin, and DETC were from Sigma-Aldrich. Fatty acid-free bovine serum albumin
(BSA) was from SeraCare. Propidium iodide, CM-H2DCFDA, DHE, and MCLA were
from Invitrogen. All synthetic oligonucleotides were from IDT (see Table 1 for primer
sequences). Restriction enzymes were from New England BioLabs.

Cell Culture. CHO-K1 cells (American Type Culture Collection) and CHO-derived cell
lines were maintained in high glucose (4.5 mg/ml Dulbecco’s modified Eagle’s medium
and Ham’s F-12 nutrient mixture (1:1)) media with 5% non-inactivated fetal bovine
serum, 2 mM L-glutamine, 50 units/ml penicillin G sodium, 50 units/ml streptomycin
sulfate, and 1 mM sodium pyruvate. C2C12 myoblasts (American Type Culture
Collection) were maintained in high glucose (4.5 mg/ml Dulbecco’s modified Eagle’s)
medium with 10% heat-inactivated fetal bovine serum, 50 units/ml penicillin G sodium,
and 50 units/ml streptomycin sulfate. NIH 3T3 cells (American Type Culture Collection)
were maintained in high glucose (4.5 mg/ml Dulbecco’s modified Eagle’s medium)
media with 10% bovine calf serum, 2 mM L-glutamine, 50 units/ml penicillin G sodium,
and 50 units/ml streptomycin sulfate. H9c2 cardiomyoblast cells (American Type Culture
Collection) were maintained in high glucose (4.5 mg/ml Dulbecco’s modified Eagle’s
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medium) media with 10% fetal bovine serum, 2 mM L-glutamine, 50 units/ml penicillin G
sodium, and 50 units/ml streptomycin sulfate. For lipotoxicity experiments, cell culture
media was supplemented with 500 µM (WT CHO and 6H2) or 250 µM (shRNA
transfected cells) palmitate complexed to BSA at a 2:1 M ratio, as described previously
(61). For ROS induction, media was supplemented with the indicated concentrations of
H2O2, menadione, or doxorubicin.

Generation of CHO Cell Mutants. Vesicular stomatitis virus G protein pseudotyped
murine retrovirus encoding the ROSAβgeo retroviral promoter trap was generated as
described previously (26, 81). CHO cells were transduced with retrovirus at a low
multiplicity of infection (1 integration per 10 genomes on average) and mutants were
isolated as described previously (7). Number of retroviral insertions within the mutant
cell genome was assessed by Southern blotting. Genomic DNA was digested with
restriction enzymes, separated by agarose gel electrophoresis, transferred to nylon
membranes, and probed with a

32

P-labeled probe corresponding to the ROSAβgeo

proviral sequence.

Cell Death Assays. Cell death was assessed by membrane permeability to propidium
iodide (PI) staining and flow cytometry (61). Following treatments, cells were harvested
by trypsinization and stained with 1 µM PI. Analyses were performed on 104
cells/sample.
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14

C Palmitate Uptake Assay. 2 × 106 cells were resuspended in 1 ml phosphate-

buffered saline (PBS) containing 500 µM

14

C-palmitate complexed to 250 µM BSA and

incubated for one minute at 37°C. Cells were washed with 10 ml PBS containing 0.1%
BSA and 500 µM phloretin, filtered, and cell-associated

14

C was quantified by

scintillation counting. A parallel aliquot of cells was used for quantification of protein by
bicinchoninic acid assay (Pierce).

Identification of Trapped Gene. The endogenous gene disrupted by retroviral insertion
was identified by 5’ rapid amplification of cDNA ends (RACE) using an oligonucleotide
tag and ROSAβgeo sequences (SMART RACE cDNA amplification kit; Clontech). The
5’ RACE product was TA cloned and sequenced, and tested for sequence similarity by
NCBI BLAST. PCR was used to verify retroviral integration within the snrpD3 gene.

Quantitative Real Time PCR (qPCR). RNA was isolated using TRIzol or TRIzol LS
reagent (Invitrogen) and reverse transcribed to cDNA using the SuperScript III Firststrand Synthesis System for RT-PCR (Invitrogen) following the manufacturer’s
instructions. Reverse transcription was performed with oligo(dT) to detect mRNA or
random hexamers to detect pre-mRNA and intron lariats. For quantification of snoRNAs
and pre-miRNAs, RNA was isolated using Trizol LS (Invitrogen). cDNA synthesis was
primed with hairpin stem-loop oligos as previously described (72), with overhang
complementarity to the 3’ end of the processed snoRNA or pre-miRNA. cDNA was
amplified for 40 PCR cycles using SYBR Green PCR master mixture (Applied
Biosystems) and 100 nM template specific primers in a ABI Prism 7500 Fast Real-Time
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PCR System. Relative quantification of gene expression was performed using the
comparative threshold method as described by the manufacturer.

Flow Cytometry Detection of Reactive Oxygen Species. Cells (2 × 105) were plated
in 12-well plates 24 h prior to various treatments. Cells were rinsed with PBS and
incubated with PBS containing 0.5 mM MgCl2, 0.92 mM CaCl2, and 1µM (C2C12 cells)
or 3 µM (CHO cells) 5-(and-6)-chloromethyl-2’,7’-dichlorodihydrofluorescein diacetate,
acetyl ester (CM-H2DCFDA, Invitrogen) in the dark at 37°C for 1 h. Cells were then
rinsed with PBS, harvested by trypsinization, and quenched with culture media. Mean
fluorescence was determined by flow cytometry on 104 cells/sample.

Generation of SmD3 antibody. For immunoblot detection of SmD3, polyclonal rabbit
anti-peptide antibody was generated from ProSci Incorporated. Animals were
immunized with the unique peptide NH2-CTGEVYRGKLIEAED-OH (murine sequence)
conjugated to KLH. Animals received six rounds of immunization followed by affinity
purification of serum.

Immunoblot Analyses. Whole cell protein lysates were prepared using RIPA buffer (50
mM Tris-Cl, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS,
and 5 mM EDTA) containing 1 mM phenylmethylsulfonyl fluoride and 1 × Protease
Complete inhibitor mixture (Roche). Subcellular fractions were isolated by sequential
detergent solubilization as described previously (40). Proteins (40 µg) were resolved by
15% (for rpL13a, SmD3, and SmB) or 12% (for hsp90, fibrillarin, lamin B1, CHOP-10,
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and β-actin) SDS-PAGE gel electrophoresis and transferred to nitrocellulose membrane
(Whatman). Membranes were probed with antibodies to rpL13a (1:500), SmD3 (1:500),
β-actin (A 2066, Sigma, 1:5000), hsp90 (SPA-846, Stressgen, 1:2000), fibrillarin (MMS581S, Covance, 1:500), lamin B1 (ab16048, Abcam, 1:1000), CHOP-10 (F-168, Santa
Cruz, 1:500), and SmB (S0698, Sigma, 1:1000). Proteins were visualized using
appropriate

horseradish

ImmunoResearch

peroxidase-conjugated

Laboratories,

1:10,000)

and

secondary

antibodies

(Jackson

chemiluminescence

reagents

(PerkinElmer Life Sciences). Band intensities were quantified by densitometry (Bio-Rad
Image Lab Software).

snoRNA Probe Synthesis and RNase Digestion. Hamster- and mouse-specific
snoRNA probes were generated with Megashortscript kit (Ambion). dsRNA templates
were generated for probe for each rpL13a snoRNA by PCR amplification of cloned
hamster or mouse rpL13a genomic sequence templates using primers containing the T7
RNA polymerase promoter and used for in vitro RNA transcription of

32

P-labeled

snoRNA probes. miR-16 probes were synthesized using templates from mirVana
miRNA Detection kit (Ambion). RNA was isolated from cells using mirVana miRNA
isolation kit (Ambion) and hybridized to

32

P-labeled RNA probes (mirVana miRNA

Detection kit) overnight at 42-52°C, followed by RNase digestion and ethanol
precipitation. RNA was separated by 10% or 15% polyacrylamide electrophoresis and
visualized by autoradiography.
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snoRNA Knockdown in vitro. Anti-sense oligos (ASOs) were designed to specifically
target murine U32a, U33, U35a, U50, U57, and U60 snoRNA sequences according to
Ideue et al. (44). For snoRNA “knock-down” experiments, 106 C2C12 myoblasts were
nucleofected using Nucleofector Kit V (Amaxa) and a total of 600 pmol of ASO.

Mapping of 2’-O-methyl modification by primer extension. Protocol was based on
methods from Lowe and Eddy (64). Total RNA from Trizol extraction was annealed with
32

P end-labeled primers at 55°C for 4 min. Primer extension reactions were carried out

in the presence of 50 mM Tris-Cl (pH 8.6), 60 mM NaCl, 9 mM MgCl2, 10 mM DTT, 1
mM dNTP, and using avian myeloblastosis virus reverse transcriptase for 30 min at
37°C. For rRNA sequencing, ddNTPs were used in individual reactions. For 2’-O’methyl
mapping, reactions were carried in “High” (4mM), or “Low” (0.004 mM) dNTP
concentrations, and 5 mM MgCl2. Reaction products were separated by 6%
polyacrylamide electrophoresis (PAGE) and visualized by autoradiography.

In situ hybridization of snoRNA probes. Synthesis and labeling of sense and
antisense RNA probes were adapted from Darzacq et al. (16). C2C12 myoblasts were
fixed in PBS containing 3% paraformaldehyde for 10 min, rinsed with PBS and
permeabilized with 0.1% Triton X-100 for 10 min at room temperature. Cells were
dehydrated serially in 70% ethanol, 95% ethanol, 100% ethanol and then air-dried.
Sequence-specific oligonucleotide probes containing aminoallyl UTP were generated
using the FISH Tag RNA Kit (Invitrogen) and labeled with an amine-reactive Alexa Fluor
594 dye. Fluorescent probe (0.5 ng/µL) was denatured in hybridization buffer (2x SSC,
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50% formamide, 10% dextran sulfate, 20 mM vanadyl ribonucleoside complexes) for 10
min at 80°C. Cells were incubated with probe/hybridization buffer at 37°C for 10 hr,
followed by sequential washes with 2x SSC, 1x SSC, 0.1x SSC all containing 1% SDS
for 15 min each at 37°C. Nuclei were counter-stained using SYTOX Green (Invitrogen).
Slides were mounted with SlowFade antifade reagent (Invitrogen). Images were
captured on a ZEISS LSM 510 META confocal laser scanning microscope using
constant pinhole size, detector gain, and offset for each probe.

Mouse model of LPS-mediated oxidative stress and in vivo snoRNA knockdown.
Female FVB mice were obtained from Charles River Laboratories and housed in
Washington University Division of Comparative Medicine facilites. Diet was standard 6%
fat breeding chow supplied ad libitum, and food was withheld at the time of LPS
injection. Between 10 and 16 weeks of age, LPS was administered at 8 mg/kg
intraperitoneally (IP), and animals were euthanized 12-24 h later. For in vivo knockdown
experiments, LNA-modified ASOs were purchased from Exiqon and used to specifically
target snoRNAs U32a, U33, and U35a. An ASO targeting GFP was used as a control.
Mice were injected IP with a total of 2.5 mg/kg of LNA every other day for a total of three
injections, and then dosed with LPS as above 48 h after the last LNA injection.
Individual snoRNA ASO concentrations were 1.25, 0.5, and 0.75 mg/kg per dose,
targeting U32a, U33, and U35a respectively (empirically determined based on
knockdown). Liver tissue was divided and either snap-frozen in liquid nitrogen (for
RNA), fixed in 10% neutral buffered formalin, or frozen in O.C.T. Compound (TissueTek). Experimental procedures were approved by the Washington University Animal
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Studies Committee and were conducted in accordance with USDA Animal Welfare Act
and the Public Health Service Policy for the Humane Care and Use of Laboratory
Animals.

In vivo detection of ROS. Formalin-fixed, paraffin-embedded samples or liver frozen in
O.C.T. were mounted on slides in serial sections by the Washington University
Anatomic and Molecular Pathology Core Lab. Detection of superoxide was performed
on frozen sections using dihydroethidium (DHE; Invitrogen, Cat# D11347). Sections
were incubated with 2 µM DHE for 30 min at 37°C or pre-treated with 200 Units/ml
PEG-SOD (Sigma), followed by co-incubation of 2 µM DHE and 200 Units/ml PEG-SOD
for 30 min at 37°C to verify the specificity of staining as indicated. For each animal (n =
4 for GFP ASO; n = 5 for SNO ASO), intensity of staining was quantified in three
independent fields from each of six sections using ImageJ software. Protein carbonyls
were detected by immunoblot using the OxyBlot Protein Oxidation Detection Kit
(Chemicon) according to the manufacturer’s instructions. Blots were quantified by
densitometry using actin as a loading control. Tissue oxysterols (7-ketocholesterol, 7keto; 3β,5α,6β-cholestantriol, triol) per mg liver protein were quantified using LC/MS/MS
as described (87).

Generation of SmD3 shRNA Clones. Hamster snrpD3 cDNA sequence was used to
design siRNA oligonucleotides using Ambion’s siRNA Target Finder Program
(ambion.com/techlib/misc/siRNA_finder.html). shRNA oligonucleotides were designed
from siRNA sequences that conferred effective knockdown in transient transfection
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assays, and each was cloned into a pSilencer 4.1-CMV hygro vector (Ambion)
containing a hygromycin resistance cassette. shRNA vectors were transfected into CHO
cells with Lipofectamine 2000 reagent (Invitrogen). Cells were plated at limiting dilution
and treated with 80 µg/ml hygromycin. Clonal lines were isolated, and SmD3
knockdown assessed by immunoblot.

Luciferase Plasmids and Transient Transfection. The split luciferase vector
containing a β-globin intron was as described previously (128). All constructs generated
by PCR or Quick-Change (Stratagene) mutagenesis were confirmed by sequencing.
The β-globin intron in the split luciferase reporter was replaced with rpL13a intron 2
containing snoRNA U32a or the rpL13a intron 2 lacking the 83 nucleotide U32a
snoRNA sequence. Cells were transfected with Lipofectamine 2000 (Invitrogen) as per
the manufacturer’s protocol and assayed 20 h post-transfection.

Luciferase Detection. Cells (3 × 104) were plated in triplicate in 96-well plates.
Following transfection of luciferase reporters as described above, cells were lysed with
Dual-Glo Luciferase Reagent (Promega) according to the manufacturer’s protocol.
Luciferase was detected using a Tecan Infinite M200 microplate reader and Magellan
software.

Microarray Sample Preparation and Data Analysis. NIH 3T3 cells (2 × 105) were
plated in 6-well plates 24 h pre-transfection. Cells were transfected with 40 pmol
LNA/DNA oligonucleotides specifically targeting GFP or SmD3 (Exiqon) using
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lipofectamine 2000 (Invitrogen) as per the manufacturer’s protocol, and total RNA was
harvested 23 h post-transfection using TRIzol reagent (Invitrogen). Resulting RNA was
quantified by A260 and A280 readings using a Nanodrop spectrophotometer (Nanodrop
Technologies) and qualitatively assessed using a BioAnalyzer 2100 (Agilent
Technolgies). cDNA was prepared using the NuGen Ovation System and microarray
data was generated with Affymetrix GeneChip Mouse Exon 1.0 ST arrays containing
266,200 probesets in the Siteman Cancer Center Molecular and Genomic Analysis
Core at Washington University. Partek Genomics Suite 6.5 was used to calculate
probeset intensities from .CEL files using the RMA algorithm with default settings at
both the gene level and probeset level. Probesets with RMA intensity below 3 across all
samples were excluded to eliminate probesets with low expression levels. Alternative
splicing multiway ANOVA was applied using Partek defaults to identify alternative
splicing events with a false discovery rate (FDR) < 0.1. Core exon level analysis was
also applied at the exon level to determine differential expression of exons not grouped
by transcript.

Transient Knockdown. For SmD3 knockdown, NIH 3T3 cells (2 × 105) were plated in
6-well plates 24 h pre-transfection. Cells were transfected with 40 pmol LNA/DNA
oligonucleotides specifically targeting GFP or SmD3 (Exiqon) using lipofectamine 2000
(Invitrogen) as per the manufacturer’s protocol, and RNA was harvested 23 h posttransfection. For SmB knockdown, NIH 3T3 cells (1 × 105) were plated in 6-well plates
24 h pre-transfection. Cells were transfected with 50 pmol control (Ambion) or snrpb
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(s74100, Ambion) Silencer Select siRNA using lipofectamine RNAiMAX (Invitrogen) as
per the manufacturer’s protocol, and RNA was harvested 24 h post-transfection.

Immunoprecipitation. For snRNA immunoprecipitation, NIH 3T3 cells were plated and
transfected as performed for SmD3 transient knockdown. 23 h post-transfection, cells
were harvested in lysis buffer (50 mM Tris-Cl pH 8, 150 mM NaCl, 0.5% Nonidet P-40)
containing 1 mM phenylmethylsulfonyl fluoride and 1 × Protease Complete inhibitor
mixture (Roche) and incubated on ice for 30 min. Cells were sonicated with five 5second pulses using a Branson Sonifier 250, incubating on ice for 20 sec between each
pulse. Cell lysates were centrifuged at 15,000 × g for 30 min at 4°C to remove insoluble
material. Cell lysates were immunoprecipitated using α-Sm Y12 antibody (ab3138,
Abcam, 1:100) or IgG control. RNA was isolated from immunoprecipitated samples
using TRIzol (Invitrogen) and reverse transcribed to cDNA using the SuperScript III
First-strand Synthesis System for RT-PCR (Invitrogen) following the manufacturer’s
instructions. Quantification of α-Sm immunoprecipitated snRNA expression relative to
control IgG precipitated snRNA was performed by qRT-PCR.

Superoxide Detection in vitro. Cells (8 × 104) were plated in 96-well opaque white
microplates 24 h prior to treatment. Cells were incubated for 1 hr in reaction buffer
containing 125 mM KCl, 10 mM HEPES, 5 mM MgCl2, 2 mM K2HPO4, and 5 µM 2methyl-6-(4-methoxyphenyl)-3,7-dihydroimidazol[1,2-A]pyrazin-3-one,

hydrochloride

(MCLA) during continuous treatment (palmitate) or rinsed with PBS and incubated in
reaction buffer immediately following treatment (doxorubicin). MCLA light emission was

90

quantified using a Tecan Infinite M200 microplate reader and iControl software. The
photomultiplier was set with an integration time of 1000 ms. The MCLA signal was
quantified in real-time or as an integral of the signal measured every 30 sec over 3 min.

Real-time Reactive Oxygen Species Detection in vitro. Cells (5 × 104) were plated in
12-well plates 24 h prior to CM-H2DCFDA loading. Cells were rinsed with PBS and
incubated with PBS containing 0.5 mM MgCl2, 0.92 mM CaCl2, and 10µM CMH2DCFDA in the dark at 37°C for 10 min. Cells were then rinsed with PBS prior to
various treatments in PBS containing 0.5 mM MgCl2 and 0.92 mM CaCl2. Mean
fluorescence was quantified every 3 min with excitation/emission wavelengths of
492/517 nm using a Tecan Infinite M200 microplate reader and iControl software.
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Table 5.1: Primer/oligo sequences
application
qRT-PCR

rpL13a qRTPCR

primer/oligo
snrpD3 forward
snrpD3 reverse
snrpb forward
snrpb reverse
β-actin forward
β-actin reverse
luciferase exon
1/intron forward
luciferase intron
reverse
Snhg5 forward
Snhg5 reverse
Nop56 forward
Nop56 reverse
U60hg forward
U60hg reverse
RPL5 forward
RPL5 reverse
Snhg3 forward
Snhg3 reverse
RPS2 forward
RPS2 reverse
EIF5 forward
EIF5 reverse
VWA5B2 forward
VWA5B2 reverse
PKD1 forward
PKD1 reverse
36B4 forward (rat)
36B4 reverse (rat)
rpL13a exon 2
forward
rpL13a exon 3
reverse
rpL13a exon 3
forward
rpL13a intron 3
reverse
rpL13a exon 4
forward
rpL13a exon 5
reverse
rpL13a exon 5
forward
rpL13a exon 6
reverse

primer/oligo sequence
5'-CGGTGTGCCGATTAAAGTCT-3'
5'-TAACATGGGTGCGTTTTTCA-3'
5'-TCTTCATCGGGACCTTCAAAGCCT-3'
5'-ACTCGCTTCTCTTCCCTTTCTGCT-3'

5'-GGCTCCCAGCACCATGAA-3'
5'-GCCACCGATCCACACAGAGT-3'
5'-CAGGTAAGTATCAAGGTTCCCG-3'
5'-CTCTTGGAAGGCAGATCTCTTG-3'
5'-CAGTGAGTGAAATGCCAGCT-3'
5'-GACAGGTGCGTTTGAAGACA-3'
5'-TGAGGAACGGCTGTCTTTCT-3'
5'-TCTTCAAGCGCTTCTTCTCC-3'
5'-CCCTTTTTGCAGGTAAGGTG-3'
5'-AAAATCCTGTTGCCTGGATG-3'
5'-CCCGAACTACAACTGGCAAT-3'
5'-CCGATGAACTTCTGCATTGA-3'
5'-AAGAAGTCGCATCGGTACTGC-3'
5'-GGTGCAAGTCCCCAAAGTTA-3'
5'-GAAAATCATGCCAGTGCAGA-3'
5'-CAAGACCAACGTGACCATTG-3'
5'-AGGCATGCTTGACACACATC-3'
5'-CAGAGCCATTTTCCTTGTCC-3'
5'-GGCAGCAACCATGACTACCT-3'
5'-TCTTGAGGAATGCACACAGC-3'
5'-GCTTCAGCAAGGTCAAGGAG-3'
5'-TGGATCCATTCCTTCAAAGC-3'
5'-CAGAGGTGCTGGACATCACAGA-3'
5'-AGTGAGGCACTGAGGCAACAG-3'
5'-CATTGTGGCAAGCAAGTGCTACTG-3'
5'-AATGTTGATGCCTTCACAGCGCAC-3'
5'-CGGAAGGTAGTCGTTGTGC-3'
5'-TGCTTGTCCAGAACTTAGGTC-3'
5'-TTTCCTCCGAAAGCGGATGAACAC-3'
5'-GGATCCCATCCAACACCTTGAGG-3'
5'-CCTCAAGGTGTTGGATGGGATCC-3'
5'-GCTTCAGCCGCACAACCTTG-3'
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snoRNA/miRNA
/tRNA reverse
transcription

rpL13a exon 6
forward
rpL13a exon 7
reverse
rpL13a exon 7
forward
rpL13a exon 8
reverse
rpL13a forward
(rat)
rpL13a reverse
(rat)
U32a SLRT
(hamster)

5'-CAAGGTTGTGCGGCTGAAGC-3'

U32a SLRT (mouse)

5'-GCGTGGTCCCGACCACCACAGCCGCCACGA
CCACGCCGAGTCTC-3'
5'-GCGTGGTCCCGACCACCACAGCCGCCACGA
CCACGCCCAGCCTC-3'
5'-GCGTGGTCCCGACCACCACAGCCGCCACGA
CCACGCACAGCCTC-3'
5'-GCGTGGTCCCGACCACCACAGCCGCCACGA
CCACGCTACTGGCA-3'
5'-GCGTGGTCCCGACCACCACAGCCGCCACGA
CCACGCTCCTGGCA-3'
5'-GCGTGGTCCCGACCACCACAGCCGCCACGA
CCACGCGTCTCA-3'
5'-GCGTGGTCCCGACCACCACAGCCGCCACGA
CCACGCTGGATCAG-3'
5'-GCGTGGTCCCGACCACCACAGCCGCCACGA
CCACGCCCAAGC-3'
5'-GCGTGGTCCCGACCACCACAGCCGCCACGA
CCACGCGCCGCC-3'
5'-GCGTGGTCCCGACCACCACAGCCGCCACGA
CCACGCTTTTGT-3'
5'-GCGTGGTCCCGACCACCACAGCCGCCACGA
CCACGCACCTGTGG-3'
5’-GTGTGGTCCCGACCACCACAGCCGCCACGA
CCACGCGTTTGTTA-3'
5'-GCGTGGTCCCGACCACCACAGCCGCCACGA
CCACGCCTGAGG-3'
5'-GCGTGGTCCCGACCACCACAGCCGCCACGA
CCACGCCTGGGG-3'
5'-GCGTGGTCCCGACCACCACAGCCGCCACGA
CCACGCGGTCAG-3'
5'-CTCAGCGGCTGTCGTGGACTGGGTGCTGCC
GCTGAGTGGTTCCCTGA-3'
5'-AAGTCAGTGATGAGCAACAATCACCATC-3'

U33 SLRT
(hamster)
U33 SLRT (mouse)
U35a SLRT
(hamster)
U35a SLRT (mouse)
U50 SLRT
U57 SLRT
U60 SLRT
U21 SLRT
U17b SLRT
U64 SLRT
ACA28 SLRT
pre-miR-1224 SLRT
pre-miR-1225 SLRT
pre-miR-23a SLRT
Glut RNA SLRT2
snoRNA/miRNA
/tRNA PCR

U32a forward
(hamster)
U32a forward
(mouse)
U33 forward

5'-GGCCTTTTCCTTGCGTTTCTCC-3'
5'-TGGGGTCGGGTGGAAATACC-3'
5'-CTTTTCTGCCTGTTTGCGTAG-3'
5'-GGCTGAAGCCTACCAGAAAG-3'
5'-CTTTGCCTTTTCCTTCCGTT-3'
5'-GCGTGGTCCCGACCACCACAGCCGCCACGA
CCACGCCAAGTCTC-3'

5'-GAGTCCATGATGAGCAACACTCACC-3'
5'-CAGCCTATGATGAAGCGATCTCCCAC-3'
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intron lariat
PCR

snRNA PCR

(hamster)
U33 forward
(mouse)
U35a forward
(hamster)
U35a forward
(mouse)
U50 forward
U57 forward
U60 forward
U21 forward
U8 forward
U8 reverse
U13 forward
U13 reverse
U17b forward
U64 forward
ACA28 forward
pre-miR-1224
forward
pre-miR-1225
forward
pre-miR-23a
forward
Glu tRNA forward
Universal reverse
primer
Universal reverse
primer 2
CHO rpL13a intron
2 sense
CHO rpL13a intron
2 antisense
CHO rpL13a intron
4 sense
CHO rpL13a intron
4 antisense
CHO rpL13a intron
5 sense
CHO rpL13a intron
5 antisense
CHO rpL13a intron
6 sense
CHO rpL13a intron
6 antisense
mouse rpL13a
intron 2 sense
mouse rpL13a
intron 2 antisense
U1 forward
U1 reverse

5'-AGCTTGTGATGAGACATCTCCCACT-3'
5'-GGCACATGATGTTCTTATTCTCACGATGGT3'
5'-GGCACATGATGTTCTTATTCTCACGATGGT3'
5'-TCTATGATGATCCTATCCCGAAC-3'
5'-GATGAACGAACTTGGCCTGACCTTC-3'
5'-CCAAGCCTGTGATGAATTGC-3'
5'-GTAGTTGGTCCTTTGATTGCATGTGATGT-3'
5'-CCTTACCTGTTCCTCCTTTCG-3'
5'-GAGCAACCAGGATGTTGTCA-3'
5'-TTTCTGGTTCATAAAGCGTGA-3'
5'-TGTCAGACGGGTAATGTGC-3'
5’-AACGGGAGCTTAGGGCATT-3’
5'-CTTTGGATTGGCCTCACAGT-3'
5'-AAGCAACACTCTGTGGCAGATGAA-3'
5'-GCGCTGTTTCAGCTCGCTTCTC-3'
5'-GTGCAGCCGGACTGACTGA-3'
5'-GGTTCCTGGGGATGGGATTTGATC-3'
5'-TAGTGGTTAGGATTCGGCGCTCTCAC-3'
5'-TCCCGACCACCACAGCC-3'
5'-GGCTGTCGTGGACTGGGTG-3'
5'-GCTCTGAGACTTGACGGTCC-3'
5'-CTCATCACTGACTTGCAGGC-3'
5'-ATCTCCCACTGGTGTTCGAG-3'
5'-CAGATTCCCCATTCTCCATG-3'
5'-TCCTTCCCAGGTGATGCT-3'
5'-TGGAAAGCTAGGCTTGCG-3'
5'-ATAATGCCACAGGCTCAGCT-3'
5'-TCTGCCAGTCTACAGGTCCC-3'
5'-TGTGAGATCAACCCATGCAC-3'
5'-CGAAAGATGGTGAGTGTTGC-3'
5'-GATACCATGATCACGAAGGTGGTT-3'
5'-CACAAATTATGCAGTCGAGTTTCC-3'
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U2 forward
U2 reverse

5’ RACE
PCR

siRNA

LNA/DNA oligos

U4 forward
U4 reverse
U5 forward
U5 reverse
U6 forward
U6 reverse
U11 forward
U11 reverse
U12 forward
U12 reverse
U4atac forward
U4atac reverse
U6atac forward
U6atac reverse
ROSAβgeo reverse
snrpD3 forward
snrpD3 reverse
ROSAβgeo reverse
snrpD3 sense
snrpD3 antisense
scrambled control
sense
scrambled control
antisense
GFP
U32a

U33

U35a

snrpD3

RNase
protection &
FISH

CHO U32 forward

CHO U32 reverse

5'-TTTGGCTAAGATCAAGTGTAGTATCTGTTC3'
5'-AATCCATTTAATATATTGTCCTCGGATAGA3'
5'-GCGCGATTATTGCTAATTGAAA-3'
5'-AAAAATTGCCAATGCCGACTA-3'
5'-TACTCTGGTTTCTCTTCAGATCGTATAAAT-3'
5'-AATTGGTTTAAGACTCAGAGTTGTTCCT-3'
5'-GCTTCGGCAGCACATATACTAAAAT-3'
5'-ACGAATTTGCGTGTCATCCTT-3'
5'-GTGCGGAATCGACATCAAGAG-3'
5'-CGCCGGGACCAACGAT-3'
5'-AACTTATGAGTAAGGAAAATAACGATTCG-3'
5'-CCGCTCAAAAATTCGTCTCACA-3'
5'-AGCGCATAGTGAGGGCAGTACTG-3'
5'-GCACCAAGGTAAAGCAAAAGCTCTA-3'
5'-AGGTTAGCACTCCCCTTGACAA-3'
5'-TGGCAATGCCTTAACCGTATG-3'
5’-CAAGGCGATTAAGTTGGGTAACGC-3’
5’-GCCGTGTAACGTTTGTGCC-3’
5’-GGACACAGTTCTCTTCCAC-3’
5’-CTCAGGTCAAATTCAGACGG-3’
5’-GCUCAUUGAAGCAGAGGACUU-3’
5’-GUCCUCUGCUUCAAUGAGCUU-3’
5’-AAGAUGAGCAUAGGAUGUU-3’
5’-AACAUCCUAUGCUCA-3’
5'+T*+C*+A*+C*+C*T*T*C*A*C*C*C*T*C*
T*+C*+C*+A*+C*+T-3'
5'

+G*+C*+G*+G*+T*G*C*A*T*G*G*G*T*T*G*+
A*+T*+C*+T*+C 3'
5'
+T*+G*+G*+T*+A*G*T*G*C*A*T*G*T*A*G*+A
*+G*+T*+C*+A 3'
5'
+T*+T*+A*+G*+C*C*T*T*T*G*G*C*A*T*T*+A*
+T*+C*+G*+G 3'
5'+T*+C*+T*+G*+T*A*T*G*T*G*A*C*T*G*
T*+G*+A*+T*+G*+T-3'
5’-TAC TGG GTA AGT TTC ATT CAG-3’

CHO U33 forward

5’-GTA ATA CGA CTC ACT ATA GGG AGG
AAG GAG TCC AGG AGG G-3’
5’-GGG TGC CAT GGA GAA TGG G-3’

CHO U33 reverse

5’-GTA ATA CGA CTC ACT ATA GGG AAG
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CGC TCT TAG CCC AGA TC-3’
CHO U34 forward

5’-GCA AGC CTA GCT TTC CAC AG-3’

CHO U34 reverse

5’-GTA ATA CGA CTC ACT ATA GGG CTG
GGA AGG AGG CTG GTG G-3’
5’-TTG CAG AGT GGT CTA GGT GG-3’

CHO U35 forward

FISH

Primer
extension

CHO U35 reverse

5’-GTA ATA CGA CTC ACT ATA GGG ACA TAT
CCC CCT ATA CAG GAG-3’

mouse U3 forward

5’-TGT AGA GCA CCC GAA ACC AC-3’

mouse U3 reverse

5’-TCC ACT CAG ACT GCG TTC C-3’

mouse rpL13a intron
1 forward
mouse rpL13a intron
1 reverse
U32a, U33: 18S
target
U32a: 28S target

5’-AAT TAA CCC TCA CTA AAAG GGA GCA
ATA AAC AGG GTG GCT GT-3’
5’-GTA ATA CGA CTC ACT ATA GGG TCC
TCA GAT GCT CAA GCA GA-3’
5’- GTAACTAGTTAGCATGCCAGAGTCTCG 3’
5’- GCTACGGACCTCCACCAGAG-3’

U35a: 28S target

5’-TCGTACTGAGCAGGATTACCATGGC-3’

Z17a, Z17b, U45a,
U45b: 18S target

5’- CCCGTCGGCATGTATTAGCTCTAG-3’

*, phosphorothioate linkage; +, LNA residue
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